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Abstract 36 
(230 words) 37 
Prediction models in healthcare aim to estimate for an individual, the probability that a condition or 38 
disease is already present (diagnostic model) or that an outcome will occur in the future (prognostic 39 
model), based on multiple predictors. 40 
Publications on prediction models have increased in recent years, and there are often competing 41 
prediction models for the same outcome or target population. Healthcare providers, guideline 42 
developers and policymakers are often unsure which model to use or recommend, and in which 43 
individuals or settings. Hence systematic reviews of these studies are increasingly demanded, required 44 
and performed. 45 
A key part of a systematic review of prediction models is to examine the risk of bias and applicability 46 
for the intended population. To help reviewers with this process, we developed PROBAST, a Prediction 47 
model Risk Of Bias ASsessment Tool for studies developing, validating or updated (e.g. extending) 48 
prediction models, both diagnostic and prognostic, models. 49 
PROBAST was developed through a consensus process involving a group of experts in the field. 50 
PROBAST includes four domains (Participants; Predictors; Outcome; Analysis) containing 20 signalling 51 
questions. This Explanation and Elaboration paper describes the rationale for including each domain 52 
and signalling question and provides guidance for reviewers on how to use these to assess risk of bias 53 
and applicability concerns. All concepts are illustrated with published examples across different topics. 54 
The PROBAST checklist and accompanying documents can also be downloaded from www.probast.org. 55 
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Introduction 56 
(532 words) 57 
Prediction models in healthcare often aim to predict for an individual, whether a particular outcome 58 
such as disease is present (diagnostic models) or will occur in the future (prognostic models).(1-6) 59 
Diagnostic models can be used to refer patients for further testing, to initiate treatment or to inform 60 
patients. Prognostic models can be used for decisions on preventive lifestyle changes, therapeutic 61 
interventions or monitoring strategies, or for risk stratification in randomised trial design and 62 
analysis.(7, 8) Potential users of prediction models include healthcare professionals, policy makers, 63 
guideline developers, patients and the general public. 64 
In the medical literature, there are thousands of studies developing and validating prediction models 65 
and often numerous prediction models for the same target population and outcomes. For example, 66 
there are over 60 models for breast cancer prognosis,(9) over 250 models in obstetrics,(10) and nearly 67 
800 models predicting outcomes in patients with cardiovascular disease.(11) This growth of prediction 68 
models will increase further with the growth of personalized or precision medicine. 69 
Systematic reviews are the most reliable form of evidence for decision makers for randomised 70 
therapeutic studies and diagnostic test accuracy studies.(12) There is growing interest in systematic 71 
reviews of prediction model studies, as exemplified by the formation of the Cochrane Prognosis 72 
Methods Group to support systematic reviews of prognosis, including prognostic model studies.(13, 73 
14) Guidance to facilitate systematic reviews of prediction models has been developed (Table 1) 74 
including for search strategies(15-18), formulating the review question (14+15), data extraction(19)), 75 
and meta-analysis (20-22). 76 
Assessment of the risk of bias (ROB) is an essential step in any systematic review. Shortcomings in 77 
study design, conduct and analysis can result in study estimates being at ‘risk of bias’, i.e. flawed or 78 
distorted results. When interpreting results from a systematic review, stronger conclusions can be 79 
drawn from a systematic review based on primary studies at low ROB rather than studies at high or 80 
unclear ROB.(44) It is also important to identify the studies with most relevance to the settings and 81 
populations targeted in the review, based on the applicability of primary studies for the review 82 
question. We developed PROBAST (Prediction model Risk Of Bias ASsessment Tool) due to the lack of 83 
suitable tools designed specifically to assess risk of bias and applicability of primary prediction model 84 
studies. 85 
PROBAST consists of four domains, with 20 signalling questions to facilitate ROB assessment.(REF M18-86 
1376] The structure and rating is similar to tools designed to assess the risk of bias in randomised 87 
trials (revised Cochrane tool, ROB 2.0), diagnostic accuracy studies (QUADAS-2) and systematic 88 
reviews (ROBIS).(42, 45, 46) Although PROBAST is initially designed for use in systematic reviews of 89 
prediction model studies, it can also be used as a general critical appraisal tool for prediction model 90 
studies. 91 
Here we describe the rationale behind the domains and signalling questions, how to use them, and 92 
how to reach domain level and overall judgements on risk of bias and applicability of primary studies 93 
to the review question. We illustrate using examples from across the medical field using six filled-in 94 
examples. As this is an area of active research, the PROBAST tool, examples and accompanying 95 
guidance will be updated when needed, and the latest PROBAST tool version should always be 96 
downloaded from the website (www.probast.org).  97 
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Focus of PROBAST 98 
(954 words) 99 
PROBAST is designed to assess primary studies that developed, validated, or updated (e.g. extended) 100 
one or more multivariable prediction models for diagnosis or prognosis (Boxes 1 and 2). A multivariable 101 
prediction model is defined as any combination or equation of two or more predictors (e.g. age, 102 
gender, disease stage, biomarkers) for estimating the probability or risk for an individual.(1, 4, 6-8, 47-103 
49) Other names for prediction model include risk prediction model, predictive model, prediction index 104 
or rule, and risk score.(1, 3-8, 49, 50) 105 
Diagnostic and prognostic models 106 
Diagnostic prediction models estimate the probability that a certain outcome, the “target condition”, 107 
is currently present. Diagnostic prediction model studies typically include individuals who are 108 
suspected of having the target condition but not yet known to have it. 109 
Prognostic prediction models estimate the probability that an outcome or event will occur, e.g. death, 110 
disease recurrence, disease complication, or therapy response. The time period of prediction can vary 111 
from hours, e.g. pre-operatively predicting post-operative nausea and vomiting, to years, e.g. 112 
predicting life-long risk of developing a coronary event. Although many prognostic models enrol 113 
patients with an established diagnosis, this does not have to be the starting point, as seen in models 114 
for predicting the development of diabetes in pregnant women(51) or of osteoporotic fractures in the 115 
general population(52). Consistent with the TRIPOD statement(7, 8), PROBAST thus uses a broad 116 
definition of prognostic models referring to the prediction of future outcomes, studied in individuals 117 
at risk of developing that outcome. 118 
Diagnostic and prognostic model studies often use different terms for predictors and outcomes (Box 2). 119 
In the cancer literature, often a distinction is made between prognostic versus predictive models, 120 
where predictive models refer to identifying individuals with differential treatment effects.(53) For this 121 
manuscript, these types of (predictive) models are out of scope. 122 
Types of predictors, outcomes and modelling technique 123 
PROBAST can be used to assess any type of diagnostic or prognostic prediction model aimed at 124 
individualised predictions, regardless of the predictors used, outcomes being predicted, or method to 125 
develop, validate or adjust the model. 126 
Predictors range from demographics, medical history and physical examination to results from 127 
imaging, electrophysiology, blood and urine measurements, pathological examinations, disease stages 128 
or characteristics, to results from -omics and any new biological measurement. Predictors are also 129 
referred to as covariates, risk indicators, prognostic factors, determinants, index test results or 130 
independent variables.(4, 6-8, 49, 54, 55) 131 
PROBAST distinguishes between candidate predictors and predictors included in the final model.(56) 132 
Candidate predictors are those variables considered to be potentially predictive of the outcome, i.e. 133 
all those evaluated in the study whether or not included in the final multivariable model. 134 
PROBAST primarily addresses prediction models for binary and time-to-event outcomes, as these are 135 
the most common in medicine. However, PROBAST can also be used to assess models predicting non-136 
binary outcomes such as continuous scores, for example pain scores or cholesterol levels, or 137 
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categorical outcomes such as the Glasgow Coma scale. Almost all PROBAST signalling questions apply 138 
equally to the assessment of prediction models for continuous and categorical outcomes, except 139 
signalling questions addressing number of outcome events per predictor, and certain model 140 
performance measures (e.g. c-statistic), which are not relevant to continuous outcomes. 141 
Prediction models usually involve regression modelling techniques such as logistic regression or 142 
survival models. Prediction models may also be developed or validated using non-regression 143 
techniques such as neural networks, random forests or support vector machines. As the use of routine 144 
big data increases, additional modelling techniques are becoming more common, such as machine and 145 
artificial learning models. The main differences between studies using regression and other types of 146 
prediction modelling include the methods of data analysis; non-regression development models can 147 
often have greater risks of overfitting when data are sparse, and the potential lack of transparency can 148 
affect the applicability and usability of the models.(57) Below we provide guidance how PROBAST can 149 
be adapted to address other types of outcomes and modelling techniques. 150 
Types of review question 151 
PROBAST can be used to assess different types of systematic review questions. For some review 152 
questions it is relevant to include all prediction model studies including both development and 153 
validation, but for other questions only validation studies would be relevant. Box 3 gives examples of 154 
potential review questions for both prognostic and diagnostic prediction models where PROBAST is 155 
applicable. The CHARMS Checklist provides explicit guidance on how to frame a focused question for 156 
reviews of prediction model studies.(19)(20) 157 
Types of prediction model studies 158 
PROBAST addresses studies on multivariable models that are to be used to make predictions in 159 
individuals, i.e. individualised predictions (Box 1), including studies on: 160 
 development of new prediction models 161 
 development and validation of the same prediction model(s) 162 
 validation existing prediction models 163 
 development of new compared with validation of existing prediction models 164 
 updating (e.g. adjusting model coefficients) or extension (e.g. adding new predictors) of 165 
existing prediction models 166 
 combinations of the above. 167 
PROBAST is not designed for assessing predictor finding studies where the aim of multivariable 168 
modelling is to identify predictors associated with outcome, rather than developing a model for 169 
individualised predictions.(19, 68, 69); the QUIPS tool has been developed for assessment of bias in 170 
these studies.(70) 171 
PROBAST is also not suitable for assessing comparative studies that quantify the impact on 172 
participants’ health outcomes of using a prediction model (as part of a complex intervention) in 173 
comparison to not using a model or an alternative (Box 1). Such comparative model impact studies use 174 
either randomised or non-randomised designs(71-74) and appropriate risk of bias tools for randomised 175 
studies (45) or non-randomised studies(75). 176 
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For diagnostic test accuracy studies, another ROB tool, QUADAS-2, has been developed.(46) However, 177 
it should be noted that some diagnostic test accuracy studies include a diagnostic prediction model. In 178 
these cases, the use of PROBAST should be considered. 179 
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Risk of bias and Applicability 180 
(335 words) 181 
Risk of Bias 182 
Bias is usually defined as presence of systematic error within a study leading to distorted or flawed 183 
study results, hampering the internal validity of that study. In prediction model development and 184 
validation, there are known features which make a study at risk of bias, although there is limited 185 
empirical evidence to demonstrate the most important sources of bias. We define risk of bias to occur 186 
when shortcomings in study design, conduct or analysis lead to systematically distorted estimates of 187 
model predictive performance. Model predictive performance is typically evaluated using measures pf 188 
calibration and discrimination, and sometimes (notably in diagnostic model studies) classification 189 
(Box 4).(8) When assessing risk of bias, it helps to think about how the equivalent hypothetical 190 
methodologically robust prediction model study would have been designed, conducted and analysed. 191 
Applicability  192 
Concerns for the applicability of primary studies to the review question can arise when the study 193 
population, predictors or outcomes of a primary study differ from those specified in the review 194 
question. For example, applicability concerns may arise when participants in the prediction model 195 
study are from a different medical setting than the targeted population defined in the review question 196 
(Table 2). A prediction model developed in secondary care may have different discrimination and 197 
calibration in primary care as patients in hospital settings typically have more severe disease than 198 
patients in primary care.(71, 86) 199 
For systematic reviews where participants, predictors and outcomes of the primary studies directly 200 
match the review question, there will likely be small concerns about applicability of the study. 201 
However, typically systematic reviews have inclusion criteria that are broader than the precise focus 202 
of the review question. 203 
We note that bias and applicability concerns should here not be confused with heterogeneity in 204 
predictive performance of a particular model across different validation studies, that may result for 205 
example from different disease severities or case-mix.(21) Variation of performance of a model across 206 
multiple validations can be reported with relevant prediction intervals, as part of investigation of 207 
heterogeneity using meta-analysis methods.(20) 208 
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Applying PROBAST 209 
(15,502 words) 210 
The PROBAST tool consists of four steps (Table 3). A PROBAST assessment should be completed for 211 
each distinct model that is relevant to the systematic review question. We use a variety of examples 212 
to illustrate key issues relating to risk of bias and applicability (Table 4). These examples address 213 
diagnostic and prognostic models, different medical areas, study designs, predictor and outcome 214 
types, and include development and validation studies. Assessments of these examples are available 215 
at www.probast.org. 216 
Step 1 – Specify your review question(s) 217 
First reviewers need to specify their review question in terms of intended use of the prediction model, 218 
targeted participants, predictors used in the modelling, and outcomes to be predicted. Structured 219 
reporting of these elements facilitates assessment of applicability. Specific guidance (i.e. the CHARMS 220 
checklist) exists to help reviewers define a clear and focused review question (19), summarized in 221 
Table 2. 222 
Step 1 is completed once per systematic review. Table 5 provides an example. 223 
Step 2 – Classify the type of prediction model evaluation 224 
In Step 2 the type of prediction model evaluation is identified to link to the relevant signalling questions 225 
in PROBAST. When both, development and validation (see Box 1) of a particular model, is of interest 226 
and reported in a single publication, each will be assessed separately. Similarly, when a certain model 227 
is being validated and adjusted or extended in the same publication. A model extension, where new 228 
predictors are added to an existing model, would be assessed as new model development. 229 
Step 2 is completed once for each prediction model assessed for the review (Table 6 provides an 230 
example). 231 
Step 3 – Assess risk of bias and applicability 232 
Assessing risk of bias 233 
PROBAST provides a structured approach to identify potential risk of bias, based on four domains with 234 
signalling questions. Signalling questions are factual questions and are rated as yes (Y), probably 235 
yes (PY), no (N), probably no (PN), or no information (NI). All signalling questions are phrased so that 236 
“yes” indicates low risk of bias, and “no” high risk of bias. The ratings of PY and PN are included to 237 
allow judgements to be made when there is not sufficient information for reviewers to be confident of 238 
making a Y or N rating. Conforming to other risk of bias tools, responses of “yes” are intended to have 239 
similar implications to responses of “probably yes” (and similarly for “no” and “probably no”), but allow 240 
for a distinction between something that is known and something that is likely to be the case.(42, 45, 241 
75) “No information” should only be used when there is truly no information to answer a signalling 242 
question.  243 
The answers to these signalling questions assist reviewers when judging the overall risk of bias for each 244 
domain. A domain where all signalling questions are answered Y or PY should be judged as “low risk of 245 
bias”. An answer of N or PN on one or more signalling question flags the potential for bias while NI 246 
indicates insufficient information. This does not mean that bias is definitely present. For example, in a 247 
prognostic study where predictors were clearly determined before event occurrence and 248 
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measurement, but the report does not state whether predictor measurements were blinded for 249 
information on the outcome occurrence, this signalling question (2.3, see below) is factually rated as 250 
NI. However, in the overall risk of bias judgement of this domain one may still judge it to be low risk of 251 
bias, since it can be inferred that predictors were measured a long time before the outcome occurred. 252 
When judging risk of bias for a particular domain, reviewers thus need to use their judgement to 253 
determine whether or not issues identified by the signalling questions are likely to have introduced 254 
bias into the model development or validation. 255 
Assessing concerns for applicability 256 
Applicability of a primary study to match the review question is assessed for the first three domains 257 
using information reported in Table 5 (the review question) and Tables 7 to 9. The analysis domain 258 
relates to limitations with the data or how the analysis was performed, which are not related to the 259 
review question, and so has no applicability assessment. The degree of applicability is rated as “low”, 260 
“high” or “unclear” concern. The “unclear” category should only be used when insufficient information 261 
is reported. 262 
If there is a good match between the review question and the primary study, there are likely to be low 263 
concerns concerning applicability. Often, a review may address a focused question but study inclusion 264 
criteria are set broader. 265 
Support for judgement and rationale for rating 266 
To improve the transparency of the assessment process, PROBAST includes two types of text boxes for 267 
each domain. The first “support for judgement” box, allows reviewers to record information that was 268 
used to answer the risk of bias signalling questions or inform the applicability assessment for that 269 
domain. Text can either be copied and pasted directly from the article being assessed, or summarised. 270 
The second text box is the “rationale for rating” allowing reviewers to record the reason for judging 271 
the model at high, low or unclear risk of bias or having high, low or unclear concerns for applicability, 272 
respectively. For example, if a domain is judged at high risk of bias, the reviewers can summarise which 273 
study features led to the rating. Or, if a domain is rated as low risk of bias despite one or more signalling 274 
questions being rated as “no”, “probably no” or “no information”, this box can be used to explain why 275 
issues identified by the signalling questions are not likely to have introduced bias into the study. 276 
Further guidance and examples are provided in the relevant domain specific sections as well as Tables 277 
7 to 10. Latest updated versions of guidance can be downloaded from www.probast.org. 278 
Domain 1: Participants 279 
This domain covers potential sources of bias and applicability concerns related to how participants 280 
were selected for enrolment into the study and the data sources used. In the support for judgement 281 
box, reviewers should describe the sources of data that were used, for example from a cohort study, 282 
randomised study, or routine care registry, and the criteria for participant selection in the primary 283 
study. 284 
Risk of bias 285 
There are two signalling questions to facilitate risk of bias judgment for this domain (Table 7). 286 
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control study data? 287 
Numerous data sources or study designs can be used in prediction model studies. 288 
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Prognostic model studies 289 
Prognostic model studies are at a low risk of bias when based on a prospective longitudinal cohort 290 
design, where methods tend to be defined and consistently applied for participant inclusion and 291 
exclusion criteria, predictor assessment and for outcome determination across a predefined follow 292 
up.(1) Using pre-specified and consistent methods ensures that the participants and related data are 293 
systematically and validly recorded. 294 
The potential for risk of bias in model development and validation studies is increased when participant 295 
data are from existing data sources, such as data from existing cohort studies or routine care registries. 296 
This is because data are often not collected using a protocol that was designed specifically for 297 
prediction model purposes but for some other purpose. For routine care registries, data relating to 298 
inclusion and exclusion criteria are often inconsistently measured and recorded.(21, 91) For example, 299 
in relation to the Clinical Practice Research Datalink (CPRD), Herrett et al. state that “the quality of 300 
primary care data is variable because data are entered by GPs during routine consultations, not for the 301 
purpose of research. Researchers must therefore undertake comprehensive data quality checks before 302 
undertaking a study”.(91) 303 
Data from one or more arms of randomised intervention trials can also be used for prognostic model 304 
development or validation. However, the randomised treatments may need to be included as separate 305 
predictors to account for any treatment effects, as effective treatments are predictors of the 306 
outcome.(92, 93) RCTs also usually have more restricted inclusion criteria typically leading to smaller 307 
distributions of the predictors (so-called smaller case-mix). It has been shown that models developed 308 
or validated using data with smaller predictor distribution (smaller case mix) tend to show a lower 309 
discriminative ability than models developed or validated from data sources where the predictors have 310 
a broader distribution.(94-97) This is because in the former the range of a model’s predicted 311 
probability is smaller and therefore the discriminative ability of the model is smaller as well.  312 
Case-cohort or nested case-control studies, in which participants with the outcome (cases) and without 313 
the outcome (non-cases or controls) are sampled from a pre-existing, well described cohorts or routine 314 
care registries of known size, can be considered at low risk of bias provided researchers appropriately 315 
adjust for the original cohort or registry outcome frequency in the analysis (see signalling 316 
question 4.6).(56, 98-101) If they do not, the study is at high risk of bias. For example, for logistic 317 
prediction models, reweighting the controls and cases by the inverse sampling fraction (from the 318 
original cohort or registry) allows correct estimation of baseline risk, allowing corrected absolute 319 
predicted probabilities and model calibration measures to be obtained.(98-101) Case-control studies 320 
in which cases and controls are not sampled from a pre-specified and well defined cohort or registry, 321 
are at high risk of bias. This is because the definition and number of the selected cases and controls 322 
relative to the source population is unclear. Accordingly, baseline risks or hazards and absolute 323 
outcome probabilities cannot be correctly adjusted for.(56)  324 
Diagnostic model studies 325 
Diagnostic models predict the presence or absence of an outcome (target disease) at the same time 326 
point as the index tests or predictors are measured (Box 2). Accordingly, the design with lowest risk of 327 
bias for diagnostic model studies is a cross-sectional study where a group (cohort) of participants is 328 
selected based on having certain symptoms or signs that makes them ‘suspected of having the target 329 
condition of interest’. Subsequently, the predictors (index tests) and outcome (disease presence or 330 
absence) according to the reference standard are measured in all participants.(102-105) Diagnostic 331 
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studies using a cross-sectional design in which the presence of disease cannot be determined in all 332 
patients by the reference standard in all patients (e.g. some participants with potential malignant mass 333 
have no lesion on imaging which can be biopsied), require additional follow-up of participants over 334 
time to establish whether the target condition was present when the index tests were performed. 335 
As with prognostic models, a diagnostic model using a nested-case-control design can only be at low 336 
risk of bias if researchers adjust the case and control samples by the inverse sampling fractions (see 337 
signalling question 4.6) to obtain correct estimate of the outcome prevalence in the original 338 
cohort.(106-110) Similarly, if a non-nested case control design is used, where advanced cases and 339 
healthy controls are over-represented, this will lead to incorrect estimates of disease prevalence and 340 
overestimated diagnostic model performance.(107-110) 341 
Example: 
In Perel 2012, data for the development of the prognostic model came from a randomised trial (CRASH-2), 
combining the data from the two treatment arms.(89) As the authors included the allocated treatment 
as a predictor in the prediction model development, this signalling question should be answered as 
Y. 
Aslibekyan 2011 used a non-nested case-control study but the authors did not adjust their analyses by 
weighting the cases and controls by the inverse of the sampling fractions.(87) Accordingly, this signalling 
question for this study should be answered as N. 
1.2 Were all inclusions and exclusions of participants appropriate? 342 
Studies that make inappropriate inclusions or exclusions of study participants may result in biased 343 
estimates of model predictive performance as the model is based on a selected subgroup of 344 
participants that may not be representative of the intended target population. 345 
Inappropriate inclusion results from including participants already known to have the outcome at the 346 
time of predictor measurement. For example, in a study developing a model to predict the future 347 
development of type II diabetes, some participants may already have type II diabetes if study inclusion 348 
criteria were based on participants without diabetes solely using self-reported criteria. Including 349 
participants who already have diabetes will most likely result in a model with overestimated predictive 350 
performance. 351 
Similarly, for a diagnostic model that aims to detect the presence or absence of pulmonary embolism 352 
in symptomatic patients, the exclusion of patients with pre-existing lung disease could be considered 353 
an example of an inappropriate exclusion. Patients with pre-existing lung disease may be harder to 354 
diagnose with pulmonary embolism than those without pre-existing lung disease; diagnostic accuracy 355 
may be overestimated if a model, after excluding these patients, is developed for use in all patients 356 
suspected of pulmonary embolism. Authors should then explicitly state that the developed model is 357 
only applicable to suspected lung embolism patients without pre-existing lung disease. 358 
Note that this signalling question is not asking about loss to follow up of participants after inclusion in 359 
the primary study (i.e. it is not about inappropriate exclusions during the study); this is dealt with in 360 
domain 4. This signalling question is about participants who were inappropriately included or excluded 361 
from the study. Further, it is important to distinguish between a selection bias imposed on a study 362 
population by restrictions in inclusion criteria, compared to a study population with different 363 
characteristics that may limit the applicability of the study to the review question (see below under 364 
applicability).  365 
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In summary, the key issue is whether any inclusion or exclusion criteria, or the recruitment strategy, 366 
could have made the included study participants unrepresentative of the intended target population 367 
for the review. Some risk of bias tools (e.g. QUADAS-2) have a signalling question asking whether the 368 
study recruited a consecutive or random sample of patients. As this is rarely achievable for any study, 369 
we have not included this as a signalling question in PROBAST.  370 
Example: 
Aslibekyan et al. excluded all participants with a fatal myocardial infarction (MI) because they used a case-
control design.(87) Participants who had died of fatal-MI were excluded as retrospective self-reported data 
could not be collected from these patients. The prediction model for non-fatal MI was thus based on selected 
healthier participants, including only those who survived an MI or did not develop a MI (controls). This is likely 
to have introduced bias as the study participants represent a selected ‘lower-risk-sample’ of the original ‘at 
risk of MI population’. Stating that the developed prediction model only predicts non-fatal MI does not solve 
the issue since at the moment of prediction it is not possible to identify participants who will develop fatal-
MI, i.e. this signalling question should be answered as PN. 
Rating the risk of bias for domain 1 371 
Table 7 shows how the signalling questions should be answered and an overall judgement for domain 1 372 
reached. 373 
Applicability 374 
Applicability for this domain considers the extent to which the population included in the primary study 375 
matches the participants specified in the systematic review question (step 1, Table 5). Consider a 376 
review with the aim of identifying all model development and validation studies to diagnose bacterial 377 
conjunctivitis in symptomatic children. The review could specify inclusion criteria such that prediction 378 
model studies with both, adults and children, were eligible. Studies that included only children would 379 
be likely to receive a rating of low concern for applicability, whereas studies conducted in adults and 380 
children may be rated as at high concern for applicability. 381 
The generalisability and thus applicability of prediction model studies based on randomised trial data 382 
needs careful consideration. Randomised trials tend to apply strict inclusion and exclusion criteria, may 383 
measure fewer predictors and outcomes, thus reducing the applicability of a model developed or 384 
validated from trial data. In contrast, distribution of study characteristics, predictors and outcomes, 385 
and thus the generalisability of prediction model studies tends to be high when data from routine care 386 
or health care registries are used for model development or validation.  387 
It is often challenging to identify when certain issues relating to a primary study are likely to introduce 388 
risk of bias or whether these are concerns for applicability. Applicability assessment is entirely 389 
dependent on the systematic review question. Consider the hypothetical pulmonary embolism 390 
example in signalling question 1.2 where reviewers might restrict the intended target population of 391 
their review, to ‘patients suspected of having pulmonary embolism without pre-existing lung disease’. 392 
For this target population, a primary study including patients with pre-existing lung disease would 393 
constitute an applicability concern and not necessarily a risk of bias. Similarly, consider a diagnostic 394 
model development study that included patients with a broad age range (18 to 90 years). This may not 395 
have introduced any bias into the primary study but it may limit the applicability of the model if the 396 
systematic review question focuses on young adults only (18 to 30 years). 397 
Finally, in a review and meta-analysis of a specific single model, that includes all validation studies of 398 
that model, risk of bias and applicability assessments should be supplemented with an investigation of 399 
heterogeneity in the reported predictive performance of that model across the validation studies. The 400 
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predictive performance of a specific model validated in other studies, is expected to be different due 401 
to differences in for example participant characteristics, healthcare setting, geographical location or 402 
calendar time periods. This does not mean there is risk of bias within the primary validation study or 403 
there are concerns about applicability; it merely reflects expected variation in predictive performance 404 
of a specific model across studies. Potential sources of heterogeneity between studies can be 405 
investigated using meta-analysis or presentation stratified by characteristics that differ across 406 
studies.(20, 21) 407 
Also note that sometimes studies validate a model that was developed in a specific group of 408 
participants, i.e. in participant data that were (for the researchers) intentionally different from the 409 
development study. For example, models developed from a healthy general population to predict 410 
cardiovascular outcomes, have been validated in patients diagnosed with type II diabetes 411 
mellitus.(111) Another example is validating the diagnostic performance of a model to diagnose deep 412 
vein thrombosis that was developed in an emergency secondary care setting in a primary care 413 
setting.(86) In both cases, heterogeneity in model performance between the development study and 414 
the validation studies should be expected. 415 
Domain 2: Predictors 416 
This domain covers potential sources of bias and applicability concerns related to the definition and 417 
measurement of the predictors. Predictors are the variables evaluated for their association with the 418 
outcome of interest, and ultimately included in combination to form the the prediction model. 419 
In the support for judgement box reviewers may list and describe how the predictors were defined, 420 
the time point of their assessment and whether other information was available when assessing the 421 
predictors. 422 
Note that for systematic reviews focusing on a specific prediction model, it is sufficient to list and 423 
describe only the predictors in the model being validated. 424 
Risk of bias 425 
There are three signalling questions to facilitate a risk of bias judgment for this domain (Table 8). 426 
2.1 Were predictors defined and assessed in a similar way for all participants? 427 
Predictors should be defined and assessed in the same way for all study participants to reduce risk of 428 
bias. If different definitions and measurements across study participants are used for the same 429 
predictors, then differences in their associations with the outcome can be expected. For example, 430 
active lower digestive tract bleeding may be included as a possible predictor in a diagnostic model 431 
developed to detect colorectal cancer. This predictor ‘blood in faeces’ could be assessed in some study 432 
participants based on visible blood in the stool and in other participants using faecal occult blood 433 
testing. However, if these methods with different minimum detection levels are used interchangeably 434 
as a single predictor, ‘blood in faeces’ has the potential to introduce bias, especially if the choice of 435 
measurement method was based on prior tests or symptoms. 436 
The potential for this bias is higher for predictors that involve subjective judgement, such as imaging 437 
test results. Here there is a risk of studying the predictive ability of the observer rather than that of the 438 
predictors.(1, 112-115) Where special skill or training is required, it may also be important to specify 439 
who assessed the predictor, for example, experienced consultant versus inexperienced trainee. 440 
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Example: 
Perel et al. assessed the following predictors, all of which were recorded on the entry form for the CRASH-2 
randomised trial: demographic characteristics (age and sex), characteristics of the injury (type of injury and 
time since injury), and physiological variables (Glasgow coma score, systolic blood pressure, heart rate, 
respiratory rate, central capillary refill time).(89) As the data used for the development of the prediction model 
came from a sub-study of a randomised trial and predictors were taken from the study entry form, it is likely – 
although not specifically described in the paper - that all predictors were defined and assessed in the same 
way for all participants. This signalling question would therefore be rated as PY. If data were derived from 
multiple sources such as in routine care data registries, where it is likely that different versions of the Glasgow 
coma scale were used or different definitions of injury type were used, then this signalling question would be 
answered as PN. 
2.2 Were predictor assessments made without knowledge of outcome data? 441 
Risk of bias is low when predictor assessments are made without knowledge of the outcome status 442 
often referred to as “blinding” or “masking”. Blinding predictor assessment to outcome data is 443 
particularly important for predictors that involve subjective interpretation or judgment, such as 444 
predictors based on imaging, histology, history or physical examination. Lack of blinding increases the 445 
risk of incorporating the outcome information into the predictor assessments which likely increases 446 
their association leading to biased, inflated estimates of model performance.(1, 112-120) 447 
Blinding predictor assessors to outcome information occurs naturally in prognostic studies using a 448 
prospective cohort design when prognostic predictors are assessed before the outcome occurs. This 449 
bias is more likely in studies using retrospective reporting of predictors (vulnerable to recall bias) or 450 
cross-sectional studies, such as diagnostic model studies, where predictors and outcomes are assessed 451 
within a similar time frame.(1, 112-121) 452 
Most prediction model studies do not report information on blinding of predictors to outcome 453 
data.(122, 123) In prognostic studies, this signalling question should then be rated as NI (Table 8). 454 
However, the domain can still be rated as low risk of bias in the overall risk of bias assessment, because 455 
if predictors were measured and reported a long time before the outcome occurred it can be inferred 456 
as ‘blinded to the outcome’. Note that even in prognostic studies predictors may sometimes still be 457 
assessed retrospectively after the outcome information has been collected, for instance predictors 458 
collected from re-interpretation of stored imaging information or when using a retrospective follow-459 
up design. An example is the re-use of frozen tissue or tumour samples to measure novel predictors 460 
(biomarkers); such samples will already be linked to participant follow-up information, and thus 461 
measurement of the novel predictors may happen after the outcome has occurred and may not be 462 
blinded to outcome information. 463 
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Example: 
Oudega et al. stated that “after informed consent was obtained, the primary care physician systematically 
documented information on the patient’s history and physical examination by using a standard form on which 
the items and possible answers were specified. Patient history included sex, presence of previous DVT, family 
history of DVT, history of cancer (active cancer in the past 6 months), immobilization for more than 3 days, 
recent surgery (within the past 4 weeks), and duration of the 3 main symptoms (a painful, red, or swollen leg). 
Physical examination included the presence of tenderness along the deep venous system, distention of 
collateral superficial veins, pitting edema, swelling of the affected limb, and a difference between the 
circumference of the 2 calves (…) After history taking and physical examination, all patients were referred to 
the hospital for D-dimer testing and leg ultrasonography”.(86) 
Since it was reported that all participants had their history and clinical information, i.e. the predictors, 
collected prior to the D-dimer testing and were therefore also blind to the outcome, this signalling question 
should be answered as Y. 
2.3 Are all predictors available at the time the model is intended to be used? 464 
For a prediction model to be usable in a real-world setting, all predictors included in that model need 465 
to be available at the point in time where the model is intended to be applied, i.e. at the moment of 466 
prediction (Table 2). This sounds so straightforward that it should always happen. Unfortunately, some 467 
models include predictors or predictor information that could not be known at the time when the 468 
model would be used. 469 
For example, when developing a prognostic model to be used pre-operatively to predict the risk of 470 
nausea and vomiting within 24 hours after surgery, the model should not include predictors such as 471 
intra-operative medication, unless this medication is pre-set and unchanged during surgery. 472 
Inappropriate inclusion of predictors not available at the time when the model would be used makes 473 
a model unusable and also inflates apparent model performance, by inclusion of predictors measured 474 
closer in time to the outcome assessment which are likely to be more strongly associated with the 475 
outcome. For predictors that are stable over time (e.g. gender and genetic factors), these aspects are 476 
not an issue. 477 
In studies that aim to externally validate an existing prediction model, the study has high risk of bias 478 
when the model is validated while not having the data of each of the predictors (in that model) but 479 
validation is done anyhow using the model simply omitting these missing predictors. This is a common 480 
flaw in validation studies and effectively produces validation results for another model, rather than a 481 
validation of the intended original developed model. In these situations, this signalling question should 482 
be answered as N. 483 
Example: 
Rietveld 2004 aimed to develop and validate a prediction model for the diagnosis of a bacterial origin of acute 
conjunctivitis in children presenting in primary care with symptoms of this disease to decide on the 
administration of antibiotics.(90) All predictors should be available to the general practitioner during the initial 
consultation. The predictors in this study were indeed all obtained during history taking and the physical exam. 
The study should therefore be answered as Y for this signalling question. If the study had included laboratory 
testing (e.g. microscopy) amongst the predictors assessed, then this signalling question would be likely to be 
answered as N. This is due to the time delay involved in obtaining microscopy results, making it unlikely that 
the GP would have the results available during the initial consultation. 
Rating the risk of bias for domain 2 484 
Table 8 shows how the signalling questions should be answered and an overall judgement for domain 2 485 
reached. 486 
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Applicability 487 
Common reasons for concerns for the applicability in this domain are that definition, assessment or 488 
timing of predictors are not consistent with the review question. Predictors should be measured using 489 
methods potentially applicable to the daily setting (Table 5) that is addressed by the review. Primary 490 
studies that used specialised measurement techniques for predictors may yield optimistic predictions 491 
for the targeted setting of the review. For example, if a model should be used in a health setting with 492 
limited access to imaging, a study that developed a model including results of positron emission 493 
tomography (PET) might not be applicable, and so may be rated as high concern. 494 
As for domain 1, there can be a subtle distinction between risk of bias and applicability assessment in 495 
this domain. Consider the example of active lower digestive tract bleeding as a predictor for colorectal 496 
cancer presence considered in signalling question 2.1. Such bleeding could be assessed based on visible 497 
blood in the stool or using faecal occult blood testing. Reviewers might focus their review to include 498 
diagnostic models that used only the ‘visible assessment’ as a predictor of colorectal cancer. With a 499 
systematic review focus on using a ‘visible assessment’ test, a primary study using a faecal occult blood 500 
test would raise applicability concerns. 501 
Similarly, as for domain 1, in reviews that aim to estimate the average predictive performance of a 502 
specific model, heterogeneity in the observed performance of that model across the development 503 
study and validation studies is expected due to differences in definition and measurement of the 504 
predictors. If different definitions or assessment methods are used, some validation studies might find 505 
different predictive performance than others and should be judged as a concern for applicability. 506 
Sometimes researchers intentionally applied different definitions or measurement methods of 507 
predictors, for example using point of care rather than laboratory testing methods for certain blood 508 
values. Again, this might not be a problem if the explicit aim of the systematic review was to include 509 
all validations of a certain model, regardless of the definition and measurement method of the 510 
predictors in that model. 511 
Domain 3: Outcome 512 
This domain covers potential sources of bias and applicability concerns related to the definition and 513 
determination of the outcome. The ideal outcome determination would classify the outcome without 514 
error in all study participants. 515 
In diagnostic model studies, the outcome is presence or absence of the target condition. Outcome 516 
determination, or verification, is measured using a reference standard (Box 2). For prognostic model 517 
studies, the predicted outcomes occur in the future, after the moment of prediction. For both 518 
diagnostic and prognostic models, the reference standard or outcome determination method may 519 
include a single test or procedure, a combination of tests (composite outcome), or a consensus by 520 
experts, e.g. an outcome adjudication committee. 521 
The support for judgement box enables reviewers to describe how the outcome was defined, 522 
determined and in what time interval, and the information available when determining the outcome. 523 
Risk of bias 524 
There are six signalling questions to facilitate a risk of bias judgment for this domain (Table 9). 525 
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3.1 Was the outcome determined appropriately? 526 
The rationale for this signalling question is to detect potential for bias due to outcome misclassification 527 
because suboptimal or inferior methods were used to determine the outcome. Errors in outcome 528 
classification can lead to biased regression coefficients, biased estimates of the intercept (logistic 529 
regression and parametric survival models models) or baseline hazard (Cox regression model), and 530 
thus biased performance measures of the prediction model. 531 
When prediction model studies use data from routine care registries or from existing studies originally 532 
designed and conducted to answer a different research question, a careful appraisal is needed to 533 
determine appropriateness of methods used for determining the outcomes, sometimes using details 534 
from earlier publications about that study. In routine care registries, outcome data might not be 535 
recorded at all, or used methods may have been suboptimal and have missed or misclassified the 536 
outcome. In diagnostic studies, problems and bias due to misclassification of the target condition by 537 
suboptimal reference standard methods have been extensively studied.(113, 117, 124-128) 538 
Similar to measurement of predictors (signalling question 2.1), the potential for bias is higher for 539 
outcomes that involve subjective judgement, such as imaging, surgical or even pathology procedures. 540 
Where special skill or training is required, it may also be important to specify who determined the 541 
outcome, for example, experienced consultant versus inexperienced trainee. 542 
Example: 
In Han 2014, “there were two defined outcomes for each of the models: one was mortality at 14 days, and 
the other was unfavourable outcome at 6 months”, defined by the authors based on the Glasgow Outcome 
Scale (GOS) as “severe disability, vegetative state, or death”. As the outcomes, mortality and the three 
categories based on the definition of GOS, use well established, appropriate measures for outcome 
determination, the signalling question should be answered as Y. 
Problems could arise if the Glasgow Outcome Scale had been measured by assessors who are not trained in 
determining this outcome. Despite the limited number of categories, misclassification is not uncommon for 
the GOS.(129, 130) The use of inexperienced assessors could lead to a less appropriate (PN or NI) answer for 
this signalling question. 
3.2 Was a pre-specified or standard outcome definition used? 543 
This signalling question aims to detect the potential risk of bias where model performance has been 544 
inflated by selecting an outcome definition that produces more favourable results.(131)  545 
The risk of bias is low when a pre-specified or standard outcome definition is used, substantiated by a 546 
definition from clinical guidelines, previously published studies or a published study protocol. Risk of 547 
bias is higher if an atypical threshold on a continuous scale has been used for defining an “outcome 548 
being present”. Biased model performance can occur if authors test multiple thresholds to obtain the 549 
most favourable outcome definition to achieve the best estimate of model performance. For example, 550 
a biased assessment of model performance would result if authors used a continuous scale such as the 551 
Glasgow Outcome Scale (GOS) ranging from 3 to 15 and chose a threshold for classifying “good” and 552 
“poor” outcomes based on achieving the best model predictive performance. 553 
Composite outcomes can also introduce risk of bias. For example, authors may introduce bias by 554 
adjusting a composite outcome definition to favour better model performance by leaving out typical 555 
components or including non-typical events. 556 
For many outcomes, there is consensus on outcome definitions, including thresholds and preferred 557 
composite outcome definitions. The COMET initiative (Core Outcome Measures in Effectiveness Trials, 558 
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http://www.comet-initiative.org) was set up to facilitate development of agreed standardised sets of 559 
outcomes. Determining whether standard or non-standard definitions have been used may require 560 
specialist clinical knowledge. 561 
Example: 
In Han 2014, “there were two defined outcomes for each of the models: one was mortality at 14 days, and 
the other was unfavourable outcome at 6 months, defined by the authors based on the Glasgow Outcome 
Scale (GOS) as severe disability, vegetative state, or death”. Given that both, mortality and the three 
categories based on the definition of GOS, are well established outcomes, i.e. standard outcome definitions 
were used, the signalling question should be answered as Y. 
If the authors instead of using a standard definition had amended the categories of the GOS based on their 
own clinical experience or following internal hospital guidance, clinical judgement should be used to decide 
whether these changes still constitute a standard outcome determination or whether the signalling question 
should be answered as PN or N. 
3.3 Were predictors excluded from the outcome definition? 562 
Outcomes should ideally be determined without information about the predictors (see signalling 563 
question 3.5), but in some cases it is not possible to avoid including predictors, for example when 564 
outcomes require determination by a consensus panel using as much information as is available. If a 565 
predictor in the model forms part of the definition or assessment of the outcome that the model 566 
predicts, it is likely that the association between the predictor and outcome will be overestimated, and 567 
estimates of model performance are optimistic; in diagnostic research this problem is generally 568 
referred to as incorporation bias.(105, 112, 116, 118, 120, 132-135) 569 
Where outcomes are difficult to determine by a single procedure (e.g. a single reference test), 570 
determination of an outcome presence or absence may be based on multiple components or tests (as 571 
in the World Health Organisation criteria for the diagnosis of myocardial infarction) or even on all 572 
available information including the predictors under study. The latter approach is known as consensus 573 
or expert panel outcome measurement and also susceptible to incorporation bias.(136) 574 
Example: 
Aslibekyan 2011 aimed to develop a cardiovascular risk score based on the ability of predictors such as dietary 
components, physical activity, smoking status, alcohol consumption, socioeconomic status and measures of 
overweight and obesity to predict non-fatal MI.(87) The study reported that MI was defined according to 
World Health Organization criteria. These criteria include cardiac biomarkers, electrocardiogram, imaging, or 
autopsy confirmation. Since the lifestyle and socioeconomic predictors used for modelling in Aslibekyan 2011 
do not form any part of this definition of MI, the study would be rated as Y for this signalling question. 
If the study had included a cardiac biomarker (e.g. troponin T at initial hospital presentation) amongst the 
predictors assessed, then this signalling question would be likely to be rated as N. This is because the initial 
troponin T measurement may have formed part of the information used to determine the outcome (MI). 
3.4 Was the outcome defined and determined in a similar way for all participants? 575 
The outcome should be defined and determined in the same way for all study participants, similar to 576 
predictors (signalling question 2.1). 577 
Outcome definition and measurement should include the same thresholds and categories to define 578 
the presence of the outcome across participants. Where a composite outcome measure is used, the 579 
results of individual components should always be combined in the same way to establish the outcome 580 
presence or absence. When using a consensus or panel-based outcome committee, the same method 581 
for establishing the outcome, for example majority vote, should be used.(132, 136, 137) 582 
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Risk of bias can arise when participants differ in the way their outcomes are determined, for example 583 
due to variation in methods between research sites in a multi-centre study. Risk of bias is also increased 584 
when prediction model studies are not based on pre-designed studies, but on data collected for a 585 
different purpose, such as routine care registry data, where inherently different outcome definitions 586 
and measurements are likely to be applied. Risk of bias is also higher when different measurement 587 
methods have different accuracy for determining the presence of an outcome (differential outcome 588 
verification) and the direction of bias is not easy to predict. For example, in a prognostic model study 589 
aimed at predicting the future occurrence of diabetes in healthy adults, the presence of diabetes in an 590 
individual can be determined in various ways which all may have different ability to determine diabetes 591 
presence or absence, e.g. using fasting glucose levels, oral glucose tolerance test or self-reported. The 592 
potential for bias is higher when outcomes require more subjective interpretation. Similarly, outcomes 593 
measured on multiple occasions such as clinic visits are at risk of bias, particularly if the frequency of 594 
measurement is different between participants; more measurement occasions increase the likelihood 595 
of detecting the outcome. 596 
In diagnostic studies, researchers sometimes explicitly did not or could not apply the same outcome 597 
measurement in each individual. For instance, in cancer detection studies, pathology results are likely 598 
to be available as a reference standard only for those participants who have some positive result on a 599 
preceding index test such as an imaging test. Two situations may then occur: partial verification, when 600 
outcome data are completely missing for the subset of participants who tested negative on the index 601 
test and for whom there is no reference standard result, and differential verification, when participants 602 
who are not referred to the preferred reference standard are assessed using an alternative reference 603 
standard of differing, usually lower, accuracy.(107, 112, 118, 120, 132-135, 138) These differences in 604 
outcome determination affect the estimated associations of the predictors with the outcome and thus 605 
the predictive accuracy of the diagnostic models., methods to account for partial and differential 606 
verification have been described.(139-142) 607 
Example: 
Han et al. 2014 validated a model to predict “unfavourable outcome after six months” in patients with severe 
traumatic brain injury.(88) The outcome was determined using the Glasgow Outcome Scale (GOS; levels 1 to 
3 on the 5-point GOS) for all patients included in this single centre study. This should be answered as Y. 
If a hospital in the study had used a different instrument to measure the outcome of interest, e.g. the 
Functional Status Examination (FSE) rather than the GOS, this would constitute a potential risk of bias as these 
tools are not directly comparable. Then this signalling question would be answered as PN or even N to 
highlight the potential risk of bias. 
3.5 Was the outcome determined without knowledge of predictor information? 608 
The outcome is ideally determined without knowledge of information about the predictors. This is 609 
comparable to intervention trials where the outcome is ideally determined without knowledge of the 610 
treatment assignment. Knowing predictor results may influence outcome determination, and could 611 
lead to biased predictive accuracy of the model, usually due to overestimation of the association 612 
between predictors and outcome.(112, 116, 118, 120, 133-135) This risk is lower for objective 613 
outcomes, such as death from any cause or whether a child birth was natural or by caesarean section, 614 
but higher for outcome determinations requiring interpretation, such as death from a specific cause. 615 
Some outcomes are inherently difficult to determine using a single measurement method or test. As 616 
discussed in signalling question 3.3, sometimes diagnostic and prognostic research cannot avoid the 617 
use of a consensus panel or end-point committees, where outcome determination includes knowledge 618 
of predictor information. If the explicit aim is to assess the incremental value of a particular predictor 619 
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or when comparing the performance of competing models (e.g. when validating multiple models on 620 
the same data set), the importance of blinded outcome determination increases to prevent 621 
overestimation of the incremental value of a particular predictor, or to prevent biased preference for 622 
one model to another. 623 
Review authors should carefully assess whether predictor information was available to those 624 
determining the outcome. If predictor information is present when determining the outcome or when 625 
it is unclear, the potential consequences should be judged in the overall judgment of bias of this 626 
domain. This overall judgment should be made taking into account the subjectivity of the outcome of 627 
interest and the underlying review question.  628 
Example: 
In the diagnostic prediction model study of Rietveld et al., the outcome of interest was a bacterial infection of 
the eye established by culture as the reference standard procedure.(90) Reading of the results of the cultures 
was somewhat subjective. Therefore, the authors of the paper explicitly inform the reader about the degree 
of blinding in their study: “The general practitioners did not receive the culture results, and the microbiologist 
who analysed the cultures had no knowledge of the results of the index tests” [read: the candidate predictors 
of the study]. The signalling question “Was the outcome determined without knowledge of predictor 
information?” should therefore be answered as Y. 
3.6 Was the time interval between predictor assessment and outcome determination 629 
appropriate? 630 
This signalling question is to detect situations where the time interval between predictor assessment 631 
and outcome determination is inappropriate, either too long or too short. Such judgement requires 632 
clinical knowledge to determine what an appropriate time interval is, and also depends on the clinical 633 
context.  634 
In diagnostic studies where the model is predicting whether the outcome (i.e. target disease 635 
determined by a reference standard) is present at the moment of prediction (Box 2), ideally the 636 
assessment of predictors (index tests) and outcome should occur at the same point in time. In practice, 637 
there may be a time interval between the moment of assessing the predictors and outcome where the 638 
diagnostic outcome classification could change, either improving or worsening. Sometimes 639 
determining the outcome presence requires clinical follow up over a time period, so a delay between 640 
predictor and outcome assessment is built into the study design, as a critical feature to reduce bias (see 641 
the example study of Oudega et al). 642 
A delay between predictor assessment and outcome determination of a few days may not be 643 
problematic for chronic conditions, while for acute infectious diseases even a short delay may be 644 
problematic. Conversely, when the reference standard involves follow-up, a minimum length may be 645 
required to capture the increase in symptoms or signs indicating that the disease was present at the 646 
moment when the predictors were assessed. Sometimes biological samples for predictor assessment 647 
and outcome determination are taken at the same time point, so the time interval during which the 648 
disease status could change is effectively zero even if the reference standard procedure on the sample 649 
is completed at a later time point. 650 
In prognostic studies, the time interval between the moment of assessing the predictors and outcome 651 
determination may also have been too short or too long to capture the clinical relevant outcome of 652 
interest.  653 
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For both diagnostic and prognostic models, there are two ways bias can present. Firstly, bias can result 654 
if outcomes are determined too early when relevant outcomes cannot be detected or the number of 655 
outcomes is unrepresentative. For example, in a model diagnosing the presence of metastases at the 656 
time of surgical removal of colorectal cancer tumour, the detection of metastases can be biased by the 657 
time point of follow-up used for the reference standard. Choice of a time point that is too early can 658 
introduce bias in the number of metastases detected, as due to limitations in current detection 659 
methods; at earlier follow-up times metastases may not have grown to a large enough size for 660 
detection. Secondly, the type of outcome may also be different depending on the time interval. For 661 
example, the metastases detected at earlier times might be mainly liver metastases, whereas at 662 
one year follow-up more bone metastases may be detected. A risk of bias then occurs if the length of 663 
interval between predictor assessments and outcome determination results in either determination 664 
of a potentially unrepresentative number of outcomes or type of outcomes (i.e. metastatic locations). 665 
The aim of a review may be specifically in either the short and long-term prognosis of a certain 666 
condition, so the time interval between predictor assessment and outcome determination is also 667 
relevant to the applicability of a study to the review question. 668 
Example: 
In Rietveld et al. where a diagnostic model is developed to predict bacterial cause in conjunctivitis eye 
infection, risk of bias in the time interval is minimised as the same clinic visit is used to measure predictors 
from patient questionnaires and physical examination, and to collect conjunctival samples for determination 
of the outcome of bacterial infection.(90) Although the reference standard results require culture for more 
than 48 hours, this is not relevant to bias, as culture results reflect disease at the time of sample collection. 
This signalling question would be answered as Y indicating a low potential for bias. 
In Aslibekyan et al. where a model is developed to predict myocardial infarction, this signalling question should 
be answered NI due to lack of information on the time interval between predictor measurement and the 
outcome determination for myocardial infarction.(87) Different time intervals could alter the number of 
myocardial infarction events that would be detected. 
Rating the risk of bias for domain 3 669 
Table 9 shows how the signalling questions should be answered and an overall judgement for domain 3 670 
should be reached. 671 
Applicability 672 
The applicability question for this domain considers the extent to which the outcome predicted in the 673 
developed or validated model matches the review question. If different definitions, timing or 674 
determination methods are used, this should be judged a concern for applicability. For example, the 675 
study might use a composite outcome which consists of components different to the ones included in 676 
the outcome definition of the review question.(143) 677 
In reviews that aim to estimate the average performance of a specific model across the included 678 
validation studies, heterogeneity in performance between the validation studies is expected due to 679 
differences in definition and measurement of the outcome. Sometimes researchers intentionally 680 
applied different outcome definitions or measurement methods. This might not be a problem if it was 681 
the explicit aim of the systematic review to include all validations of the model, regardless of outcome 682 
definition and measurement method. 683 
Domain 4: Analysis 684 
The use of inappropriate analysis methods, or the omission of important statistical considerations, 685 
increases the potential for bias in the estimated predictive performance of a model. Domain 4 686 
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examines whether key statistical considerations were correctly addressed. Some of these aspects 687 
require specialist knowledge and we recommend that this domain is assessed by at least one individual 688 
with statistical expertise in prediction model studies. The support for judgement box should list and 689 
describe the important aspects needed to address this domain.  690 
Risk of bias 691 
There are nine signalling questions to facilitate a risk of bias judgment for this domain (Table 10). 692 
4.1 Were there a reasonable number of participants with the outcome? 693 
As applies for all medical research, the larger the sample size the better, as it leads to more precise 694 
results, i.e. smaller standard errors and narrower confidence intervals. For prediction model studies, it 695 
is not just the overall sample size that matters but more importantly the number of participants with 696 
the outcome. For a binary outcome, the effective sample size is the smaller of the two outcome 697 
frequencies, ‘with the outcome’ or ‘without the outcome’. For time-to-event outcome, the key driver 698 
is the total number of participants with the event by the main time-point of interest for prediction. 699 
More importantly, in prediction model studies the number of participants with the outcome not only 700 
influences the precision but also affects predictive performance, i.e. is a potential source of bias. What 701 
is considered a reasonable number of participants with the outcome (yielding low risk of bias) differs 702 
between model development and validation studies. 703 
Model development studies 704 
The performance of any prediction model is to varying extents overestimated when the model is both 705 
developed and its performance assessed on the same dataset.(49, 81, 147, 148) This overestimation is 706 
larger with smaller sample sizes and notably with smaller number of participants with the outcome. 707 
Concerns about optimistic performance are exacerbated when the predictors included in the final 708 
model are selected from a large number of candidate predictors, relative to a low number of 709 
participants with the outcome, and when predictor selection was based on univariable analysis (see 710 
signalling question 4.5). Sample size considerations for model development studies have, historically, 711 
been based on the number of events-per-variable. More exactly, it is the number of events relative to 712 
the number of regression coefficients that need to be estimated for the candidate predictors. For 713 
example, a candidate predictor with six categories will require five degrees of freedom (five regression 714 
coefficients are estimated). Also, the word candidate is important as it is not the number of predictors 715 
included in the final model but rather the total number of predictors that were considered during any 716 
stage of the prediction model process.  717 
While an EPV of at least 10 has been widely adopted as a criterion to minimize overfitting(149-151), 718 
recent studies have shown that EPV of 10 has no scientific basis(146) and various authors suggested 719 
higher EPVs of at least 20.(146, 152, 153). In general, studies with fewer than 10 EPV are likely to suffer 720 
from overfitting, whilst those with an EPV of more than 20 are less likely to suffer from overfitting. 721 
However, the sample size needed to minimize overfitting is context specific, dependent on outcome 722 
prevalence, overall model performance (R-squared), and the predictor distributions.(144-146) 723 
Therefore it may be difficult to decide whether an appropriate sample size was used, especially when 724 
EPV is between 10 and 20. Prediction models developed using machine learning techniques often 725 
require substantially higher EPV to minimize overfitting, with an EPV of at least 200 often needed.(57)  726 
Hence, the smaller the effective sample size and the lower the EPV, the higher the risk the final 727 
prediction model has included spurious predictors (so-called overfitted models) or failed to include 728 
important predictors (underfitting). Overfitting and underfitting are likely to yield biased estimates of 729 
the model apparent predictive performance.(49, 50, 81, 147, 148, 154) With small EPV, authors need 730 
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to quantify the extent of misfitting of the developed prediction model, for example by using internal 731 
validation techniques. Based on this internal validation, optimism-adjusted estimates of model 732 
performance can be produced and model parameters adjusted (i.e. shrink regression coefficients) to 733 
decrease this bias (see signalling question 4.8). 734 
Model validation studies 735 
In a validation study, the aim is to quantify the predictive performance of an existing model using a 736 
separate dataset from the model development.(8, 49, 81, 155-157) Emphasis in a validation study is 737 
on accurate and precise estimation of model performance so that meaningful conclusions can be 738 
drawn. Sample size recommendations for validation studies are that at least 100 participants with the 739 
outcome are needed, otherwise the risk of biased estimates of model performance increases.(77, 78, 740 
158) 741 
Example: 
Aslibekyan et al. developed two prognostic models (one including only easy to obtain predictors and one 
extended with various dietary and blood markers) to predict the risk of developing myocardial 
infarction (MI).(87) Although the authors used a case-control study design and many inclusion and exclusion 
criteria, they ended up with 839 cases with an MI for developing score 1 and 696 for score 2. The exact number 
of candidate predictors is not explicitly mentioned but from the methods and supplementary tables 1 and 2 
we can estimate that the authors likely used 20 to 30 predictors or rather degrees of freedom as they 
categorised several continuous predictors into quintiles. This indicates that the EPV is between (taking the 
smallest number of events) 696/20 (i.e. 35) and 696/30 (i.e. 23). As the EPV in either case is much larger than 
10, this signalling question should be answered Y, indicating a low risk of bias. 
Oudega et al. validated a diagnostic model for detecting the presence of deep vein thrombosis (DVT) in 
patients who consulted with their primary care physician about symptoms suggestive of DVT.(86) The total 
sample size of their validation study was 1295 patients with symptoms of DVT of whom 289 had an DVT (as 
detected by D-dimer and leg ultrasonography). Since, the number of events is larger than the recommended 
100 events needed for validation, the signalling question, for this validation study, should be answered as Y, 
indicating a low risk of bias. If this number was lower, e.g. 80 or 40 patients with DVT, then the answers for 
this example would be PN or N, respectively. 
4.2 Were continuous and categorical predictors handled appropriately? 742 
Dichotomisation of continuous predictors, such as age and blood pressure, should be avoided.(159-743 
161) Dichotomisation requires choosing an often arbitrary cut-point value, for example above which 744 
participants, are classified as high (or abnormal) and below which they are classified as low (or normal). 745 
The usual fallacious argument for the approach is to aid clinical interpretation and maintain simplicity. 746 
However, it leads to loss of information and reduced predictive ability of a prediction model including 747 
dichotomised continuous predictors can be substantial.(159-162) 748 
For example, dichotomising a variable at the median value has been shown to reduce power by about 749 
the same amount as discarding a third of the data.(163) Also, the range of model predicted risks across 750 
the spectrum of predictor values is lost: individuals just below the cut-point are assumed to have a 751 
different risk from those just above the cut-point, even though their predictor values barely differ. 752 
Conversely, two individuals with very different values but both above (or both below) the cut-point 753 
are assumed to have identical risks. Linear (or non-linear) relationships between the predictor and 754 
outcome risk are therefore lost. When a predictor is categorised using widely accepted cut-points, 755 
although information has been lost, there is a low risk of bias since the predictor cut-point was pre-756 
defined.  757 
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Model development studies 758 
A developed model is at low risk of bias when included predictors are kept as continuous. The 759 
association between the predictor and outcome risk should still be examined as linear or non-linear by 760 
using, for example, restricted cubic splines or fractional polynomials.(49, 81, 164) 761 
A developed model is at high risk of bias when dichotomised continuous predictors are included, 762 
especially when (i) cut-points were chosen via data-dredging on the same data set, for example to 763 
identify the ‘optimal’ cut-points that maximises predictor effects or minimises associated p-764 
values;(159-162) and (ii) a selection procedure was used to identify the ‘significant thresholds’.(49, 81) 765 
Risk of bias is decreased when the model uses categorisation of continuous predictors into four or 766 
more groups, rather than dichotomising, especially when it is based on widely accepted cut-767 
points.(160, 162) However, for classification of low-risk of bias, it should be clear that the number and 768 
placement of cut-points of predictors was chosen in advance of data analysis. For similar reasons as 769 
discussed for signalling question 4.1, an internal validation followed by optimism-adjustment of model 770 
performance and prediction model parameters, also decreases the risk of bias (see also signalling 771 
question 4.8). For model development studies which have dichotomised continuous predictors after 772 
the data analysis and did not adjust for it by applying internal validation and shrinkage techniques, this 773 
signalling question should be answered as N. 774 
Model validation studies 775 
In model validation studies, the model as originally fitted in the development data should be evaluated 776 
on its predictive accuracy in the validation dataset. This means that the originally reported intercept (or 777 
baseline hazards) and regression coefficients are used for exactly the same format of the predictors. 778 
For example, if body mass index (BMI) is originally included as dichotomised in the model, then 779 
validation studies should use BMI values dichotomised at the same cut-point and not BMI as 780 
continuous or dichotomised using a different cut-point. If predictors do not have the same format in 781 
the validation as used in the development model, the validation might be considered at high risk of 782 
bias since the predictor-outcome association (the regression coefficient) of BMI from the development 783 
study was effectively used in the validation study for a different version of the predictor. 784 
Example: 
Oudega et al. validated the Wells rule for identifying individuals with deep vein thrombosis (DVT).(86) 
However, the authors comment that “the last item of the rule—presence of an alternative diagnosis— has 
never been unambiguously defined and often causes controversy among users of the rule. In our study, 
physicians were asked to give their own assessment of the patient’s probability of having DVT by using a score 
of 1 to indicate high probability of DVT, no alternative diagnosis likely; 2 to indicate moderate probability of 
DVT, alternative diagnosis possible; or 3 to indicate low probability of DVT, alternative diagnosis certain. To 
tailor the judgment of the physician on this item, 7 common alternative diagnoses for patients with suspected 
DVT were provided on the study form. If a low or moderate probability was assigned to a patient, we 
subtracted 2 points from the Wells score in the analysis”. Since this is not a true deviation from the original 
definitions, this signalling question should be answered as Y. 
Perel et al. developed a prediction model (CRASH-2) for early death in patients with traumatic brain injury, 
and during model development they take a three category variable ‘type of injury’ (penetrating, blunt, or blunt 
and penetrating) and analyse it as a two category variable (penetrating versus a combined category of blunt 
and penetrating), the rationale for this is not given.(89) Nevertheless, continuous variables were analysed as 
continuous in the model development, and so the collapse from 3 to 2 categories for this variable was probably 
due to few participants or events being in the ‘blunt’ category. Further, the type of injury was not subsequently 
included in the final model, and so it is unlikely that reduction in predictor categories was done in order to 
improve statistical significance for this predictor. Therefore, we would rate the signalling question as Y. When 
externally validating the CRASH-2 model, the authors “applied the coefficients of the model developed in 
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CRASH-2” and appear to use the same predictors and scale as originally coded, and thus an answer of Y seem 
appropriate. 
4.3 Were all enrolled participants included in the analysis? 785 
As applies to all types of medical studies, all participants enrolled into a study should be included in 786 
the data analysis, otherwise there is a potential for risk of bias.(46, 112, 165, 166) This signalling 787 
question relates to exclusion of participants from the original study sample who met the inclusion 788 
criteria. It is not about inappropriate inclusion criteria (which are addressed in signalling question 1.1) 789 
and not about the handling of missing data in predictors or outcomes (which is covered in signalling 790 
question 4.4). 791 
Enrolled participants are often excluded due to uninterpretable (unclear) findings, outliers or missing 792 
data in predictors or outcomes (due to loss to follow up). Outlier, uninterpretable or missing values 793 
occur in all types of medical research. Omitting enrolled participants from analysis can lead to biased 794 
predictor-outcome associations and biased predictive performance of the model, if the remaining 795 
analysed individuals are not a completely random but rather a selective subsample. The relationship 796 
between predictors and outcomes is then different for the analysed versus the excluded participants. 797 
For example, excluding participants from the study sample where predictor values (e.g. imaging or lab 798 
test results) were unclear likely yields a study sample with participants in the extremes of the predictor 799 
range. This in turn may result in biased, overestimated, model discrimination.(166) When only a low 800 
percentage of enrolled participants are not included in the analysis, there may only be a low risk of 801 
bias. However, a minimal or acceptable percentage is hard to define as it depends on which 802 
participants were excluded, and whether it was a selected subsample or not. The risk of bias increases 803 
with an increasing percentage of participants excluded.  804 
Prediction model studies based on routine care databases or registries, where participants are not 805 
formally enrolled in some study and data are originally collected for other reasons, are particularly 806 
susceptible to this form of bias. When such data sources are used for model development or validation, 807 
participant selection should be based on clear inclusion criteria. We note that in such routine care 808 
datasets, the extent of potential bias may sometimes be unclear due to unreported information 809 
relating to specific inclusion criteria and reasons for exclusion of included participants. 810 
Example: 
In Han et al., all 300 participants met the inclusion criteria for validation of three versions of the IMPACT 
models for TBI referred to as core, extended and laboratory IMPACT models.(88) Thirty-six participants (12%) 
were excluded from validation of the laboratory version of the IMPACT model due to missing data on blood 
glucose level, however all participants could be included for both the core and extended IMPACT models. For 
assessment of the core and extended CT models, the signalling question would be answered as Y as all 
participants are included in the analysis. For the assessment of the laboratory model, the signalling question 
would be answered as either PN or PY, depending on the concern from exclusion of 36 (12%) of participants 
from the analysis. This would depend on clinical knowledge and judgement of whether the missing glucose 
measurements are likely to be associated with the severity of patient TBI. 
4.4 Were participants with missing data handled appropriately? 811 
As noted in the previous item, simply excluding enrolled study participants with any missing data from 812 
the analysis leads to biased predictor-outcome associations and biased model performance when the 813 
analysed individuals are not a completely random sample from the original full study sample but rather 814 
a selective subsample.(167-177) When there is no mention of missing data in a study report, it is likely 815 
that participants with any missing data have simply been omitted from any analyses (so-called 816 
available case or complete-case analysis) as statistical packages automatically exclude individuals with 817 
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any missing value on any of the data analysed unless prompted to handle otherwise. Reviews showed 818 
that available or complete case analysis is the most common way to handle missing data in prediction 819 
model studies.(68, 178-186) 820 
The most appropriate method for handling missing data is multiple imputation as it leads to the least 821 
biased results with correct standard errors and p-values.(167-173, 175-177) In prediction model studies 822 
multiple imputation is superior in terms of bias and precision to other methods, both in model 823 
development(173, 176, 187) and validation studies(176, 188-190). In contrast to uninterpretable or 824 
outlier data, the use of a separate category to capture missing data is not an appropriate method for 825 
handling participants with missing data. The use of this missing indicator method leads to biased 826 
results in prediction model studies and this signalling question should then be rated as N.(172, 177) The 827 
risk of bias due to missing data increases with increasing percentages of missing data, but a minimal 828 
acceptable percentage which can be used as a threshold for a low risk of bias is hard to define.(173) 829 
To judge a possible risk of bias, it is useful when authors provide the following: the 830 
distributions (percentage, mean or medians) of the predictors and outcomes between both groups 831 
(excluded versus analysed participants); or a comparison of the predictor-outcome associations and 832 
the model predictive performance with and without inclusion of the participants with missing values. 833 
If results are similar with and without participants with missing values, there is a strong indication that 834 
the results of the analysis are less likely to be biased. If such comparison is not presented and 835 
investigators have not used an imputation method, we recommend to rate this signalling question as 836 
PN or N, certainly if a relevant proportion of participants are excluded due to missing data. 837 
Sometimes, when a model is validated in other data and a predictor of the model is systematically 838 
missing (e.g. not measured), authors validate the model by simply omitting the predictor from the 839 
model and validate the original model (i.e. the original predictor weights or regression coefficients) 840 
without that predictor. This leads to a high risk of bias and such studies should be rated as N for this 841 
question. If the model had originally been fit without the omitted predictor, all the remaining predictor 842 
coefficients would be different. 843 
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Example: 
Perel et al. developed a prognostic model from a data set with ‘very low amount of missing data and therefore 
they did a complete case analysis’.(89) The authors showed in the same paper an external validation of this 
developed model where they applied multiple imputation. It was neither clear from the development study 
how low the number of participants with missing data was nor was any comparison given between the 
completely observed and excluded set of participants, making it hard to judge whether there was some risk 
of bias in the model development. In the validation study the authors used multiple imputation indicating that 
they know the procedure; if it was needed to multiply impute missing data in the development sample, they 
likely would have used multiple imputation as well. Accordingly, this signalling question should strictly be 
answered as NI for the development and Y for the validation part of the paper, although PY for the 
development part would also be possible. 
In Aslibekyan et al., the authors state that for their model development complete case analysis, with 10% of 
participants being excluded, was used. No information was provided to confirm that complete case analysis 
was a valid approach, i.e. that the included and excluded participants were similar, or that the included 
participants approximated to a completely random subset of the original study sample.(87) Accordingly this 
signalling question should be rated N for the development part. For the model validation, there was no 
mention of missing data or handling of missing data. Accordingly, the answer for this signalling question for 
the model validation should strictly be NI, but perhaps even PN as all clinical studies tend to have some missing 
data. 
4.5 Was selection of predictors based on univariable analysis avoided? (Model development 844 
studies only) 845 
Often many features are available in a dataset that could be used as candidate predictors, and in many 846 
studies researchers want to reduce the number of predictors during model development to produce a 847 
simpler model. 848 
In a univariable analysis, individual predictors are tested for their association with the outcome. Often 849 
researchers select the predictors with a statistically significant univariable association (e.g. at p-850 
value < 0.05) for inclusion in the development of a final prediction model. This method can lead to 851 
incorrect predictor selection for developing the model as predictors are selected based on their 852 
statistical significance as a single predictor rather than in their context with other predictors.(49, 81, 853 
191) Bias occurs when univariable modelling results in omission of variables from the model because 854 
some predictors are only important after adjustment for other predictors, known from previous 855 
research to be important, did not reach statistical significance in the particular development set, for 856 
example due to small sample size. Also, predictors may be selected in univariable selection based on 857 
spurious (accidental) association with the outcome in the development set. 858 
A better approach to decide on omitting, combining or including the candidate predictors in the 859 
multivariable modelling is to use non-statistical methods, i.e. without any statistical univariable pre-860 
testing of the associations of the predictors with the outcome. Better methods include those based on 861 
existing knowledge of yet established predictors in combination with the reliability, consistency, 862 
applicability, availability and costs of predictor measurement relevant to the targeted setting. It is 863 
recommended that predictors with clinical credibility and those already well established are included 864 
and retained in a prediction model regardless of any statistical significance.(49, 81, 192) Alternatively, 865 
some statistical methods that are not based on prior statistical tests between the predictor and the 866 
outcome, can be used to reduce the number of modelled predictors, for example principal components 867 
analysis (PCA). 868 
During modelling, predictor selection strategies may be used to omit predictors (e.g. backwards 869 
selection procedures) and to fit a smaller, simpler final model.(49, 81, 192) However, the effects of 870 
using such multivariable predictor selection strategies on the potential overfitting of the prediction 871 
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model to the development data at hand should be tested using internal validation and optimism-872 
adjustment strategies which are discussed in signalling question 4.8. 873 
When the model development correctly avoids univariable selection or there is no evidence of 874 
univariable selection for predictions prior to the multivariable modelling, studies should be rated as Y 875 
or PY. When predictors are selected based on univariable analysis prior to multivariable modelling, the 876 
signalling question for these studies should be answered as N. 877 
Example: 
In Perel et al., before developing the model, potential users of the model were consulted to identify candidate 
predictors and interactions based on known importance and convenience to the clinical settings of pre-
hospital, battlefield and emergency departments.(89) The researchers then included all so defined candidate 
predictors in the multivariable analysis. Decisions on which predictors were eventually retained in the final 
prediction model were based on clinical reasoning, availability of predictor measurement at the time the 
model would be used, and practicalities of collecting predictors using equipment in the clinical settings. 
Although there is a possibility that other predictors could have been considered important, the choice of 
predictors was not based on potentially biased univariable selection of predictors. The study would therefore 
be answered as Y for this signalling question. 
In Rietveld et al., predictor selection based on univariable analysis (p value of ≤ 0.10) was used to select 
predictors for the multivariable model.(90) This study would be therefore answered as N for this signalling 
question. If all predictors had been entered into multivariable analysis without the prior univariable selection, 
an answer of Y would have been given. 
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of controls) accounted 878 
for appropriately? 879 
The development and validation of prediction models must ensure that the statistical methods used 880 
and their underlying assumptions are appropriate for the study design and type of outcome data 881 
analysed. Here, we draw attention to some key considerations related to complexities in the data that 882 
can lead to risk of bias of the estimated predictive performance of the model if not appropriately 883 
accounted for in the analyses.  884 
As discussed under signalling question 1.1, if a case-cohort or a nested case-control design was used 885 
for a prediction model then the analysis method must account for the sampling fractions (from the 886 
original cohort) to allow for proper estimation of the absolute outcome probabilities.(98, 100, 106, 887 
110) For example, in a diagnostic prediction model (development or validation) study that used a 888 
nested case-control design where a fraction of all the controls were sampled from the original cohort, 889 
a logistic regression in which the controls are weighted by the inverse of their sampling fraction needs 890 
to be applied instead of a standard logistic regression, otherwise the predicted risks by the model will 891 
be biased. When such appropriate adjustments for sampling fractions are made, they alleviate the risk 892 
of bias concerns raised in signalling question 1.1. If not done, one should score a N only once to either 893 
signalling question 1.1 or this signalling question.  894 
For prognostic models to predict long term outcomes in which censoring occurs, it is important that a 895 
time-to-event analysis such as a Cox regression is used to include censored individuals up to the end 896 
of their participant follow-up. It is inappropriate to use logistic regression models that simply exclude 897 
censored participants with incomplete follow-up. Using a flawed logistic regression approach leads to 898 
a selected dataset with fewer individuals without the outcome which biases predicted risks as 899 
individuals with outcome are overrepresented. Time-to-event analysis correctly deals with these 900 
censored individuals. 901 
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When there are prominent competing risks these should also be accounted for in the time-to-event 902 
analysis when developing a prognostic model. An example of competing risks would be in a model for 903 
occurrence of a second hip replacement where death in elderly patients with a first hip replacement 904 
may occur before the second hip replacement. If competing risk is not correctly accounted for then 905 
absolute risk predictions will be overestimated and biased as patients with the competing event are 906 
simply censored.(193) 907 
Also, correct modelling methods are needed where multiple events per individual can occur, such as 908 
in a model of epilepsy seizure, where some individuals experience more than two seizures. Multi-level 909 
or random effects (logistic or survival) modelling methods would be needed to avoid underestimation 910 
and bias in predictor effects.(194-197) 911 
Statistical expertise will be required to identify these and potentially other issues in specific studies. 912 
The issues we have highlighted here will typically be the most important to be aware of in prediction 913 
modelling studies. If it is deemed that key statistical complexities are being ignored in a study, there 914 
may be a strong indication of a high risk of bias on this signalling question. 915 
Example: 
In Aslibekyan et al., a conditional logistic regression model was used to develop a prognostic prediction model 
for MI.(87) Included participants provided data between 1994 and 2004, however, it is unclear whether all 
individuals had predictor values recorded at the start of the period, or whether they could enter post-1994 
and thus have a shorter follow-up. If all individuals entered with predictor values at 1994, then the model 
would predict risk of MI by 10 years (i.e. by 2004) and be interpretable. However, if some individuals entered 
after 1994, then the interpretation and bias of the logistic model is a concern because predictions are not 
specific to a particular time-period and the length of follow-up is being ignored. If participants had different 
times of follow up, it would be better for a survival analysis model to be fitted to allow risk predictions over 
time and delayed entry of participants. Further, it is not clear how prevalent the competing risk of death due 
to other non-MI conditions was, even though the included population went up to an age of 86 years. Such 
issues may be a consequence of the case-control (rather than cohort) nature of the study. Thus, risk of bias 
was not avoided (PN) due to these statistical complexities. 
In Rietveld et al., the development of a diagnostic model using standard logistic regression was relatively 
straightforward as the developed model aimed to predict risk of having a bacterial conjunctivitis using a full 
cohort approach (without sampling) and therefore did not involve follow-up, censoring or competing 
events.(90) In this case, the signalling question should be answered as Y. 
4.7 Were relevant model performance measures evaluated appropriately? 916 
Box 4 provides an overview of the various performance measures of a multivariable prediction model. 917 
PROBAST is designed to assess studies on multivariable models that are developed or validated to 918 
make predictions in individuals, i.e. individualised predictions (Box 1). Accordingly, to fully gauge the 919 
predictive performance of a model, both model calibration and discrimination (such as the c-index) 920 
addressing the entire range of the model predicted probabilities, need to be assessed.(7, 8) If 921 
calibration and discrimination are not assessed, the study is at risk of bias as the ability or performance 922 
of the model to provide accurate individual probabilities is not completely known (Box 4). 923 
When calibration plots or tables are observed with small numbers of groups (e.g. possibly due to a 924 
small sample size with too few events), judgment of the plot is required to rate this signalling question 925 
properly. In the absence of a calibration plot or table comparing predicted versus observed outcome 926 
probabilities, studies reporting only a statistical test of calibration should be rated N for this signalling 927 
question. 928 
Additionally, the methods used to assess model calibration and discrimination should also be 929 
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appropriate for the outcome the model is predicting. Approaches used to assess calibration and 930 
discrimination for models predicting a binary outcome developed using logistic regression will not be 931 
suitable for models predicting long term outcome occurrences, such as 5-year mortality or survival, 932 
using Cox regression as censoring needs to be accounted for. Failure to account for censoring when 933 
assessing prognostic model calibration and discrimination – either in a development or validation study 934 
- means the study should be answered as N or PN for this signalling question. 935 
Some studies additionally provide classification measures such as sensitivity, specificity, predictive 936 
values or reclassification measures, such as the net reclassification index (NRI), to indicate a model 937 
predictive performance, sometimes without providing the model calibration and c-index (Box 4). 938 
Classification measures are most commonly provided in diagnostic model studies. Estimation of 939 
classification, as well as reclassification, parameters requires the introduction of one (or more) 940 
thresholds in the range of the model predicted probabilities. Using thresholds allows the reporting of 941 
model predictive performance at potentially clinically relevant probability thresholds, as opposed to 942 
entire range of the model predicted probabilities. Nevertheless, the use of probability thresholds 943 
typically leads to loss of information, since the entire range of predicted probabilities of the model is 944 
not fully utilised, and choice of thresholds can be data driven rather than pre-specified based on clinical 945 
grounds (see also signalling question 4.2). This practice can cause substantial bias in the estimated 946 
(re)classification measures, certainly when thresholds are chosen to maximise apparent 947 
performance.(84, 198) When the choice of threshold is not pre-specified, these methods are subject 948 
to risk of bias and this signalling question should be answered N. Also, when classification and 949 
reclassification measures are reported without model calibration, this signalling question should be 950 
answered as N. Before categorising model predicted probabilities, calibration is needed to understand 951 
whether the predicted probabilities are correct (Box 4). 952 
Example: 
In the study by Rietveld et al., the authors assessed the calibration by calculating the Hosmer-Lemeshow test, 
which resulted in a p-value of 0.117; this was interpreted that the model was well calibrated.(90) If this was 
the only measure to assess calibration of the model this signalling question would be rated as N as such p-
value does neither indicate whether there was any miscalibration nor the magnitude of any miscalibration. 
However, in Table 4 the authors present the mean predicted probabilities with confidence intervals across 
subgroups and the corresponding observed outcome frequencies. This calibration table gives an indication of 
the model calibration, such that the answer to the signalling question for this study would be PY. 
In the validation of their model for predicting early death in patients with traumatic bleeding, Perel and 
colleagues evaluated calibration by presenting calibration plot of observed risks against predicted risks 
grouping by tenth of predicted risk.(89) Presenting calibration in this format allows the reader to judge the 
accuracy of the model over the entire probability range. The plot could be enhanced by overlaying the figure 
with a non-parametric (lowess) smoother. The authors also reported a c-index, enabling readers to judge the 
discrimination ability of the model although there was no 95% confidence interval to indicate the uncertainty 
of the estimate. This study would be at low risk of bias and answered as Y for this signalling question. 
4.8 Was model overfitting and optimism in model performance accounted for? (Model 953 
development studies only) 954 
As discussed under signalling questions 4.1, 4.2 and 4.5, quantifying the predictive performance of a 955 
model on the same data from which the model was developed (apparent performance) tends to give 956 
optimistic estimates of performance due to overfitting, i.e. the model is too much adapted to the 957 
development data set. This optimism is higher when any of the following are present: total number of 958 
outcome events is small; too few outcome events relative to the number of candidate predictors is 959 
present (small EPV); dichotomisation of continuous predictors; predictor selection strategies based on 960 
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univariable analyses are used; or traditional stepwise predictor selection strategies (e.g. forwards or 961 
backwards selection) in multivariable analysis in small data sets (small EPV) are used.(49, 81) 962 
Therefore, studies developing prediction models should always include some form of internal 963 
validation, such as bootstrapping and cross-validation. Internal validation is important to quantify 964 
overfitting of the developed model and optimism in its predictive performance, except when sample 965 
size and notably EPV are extremely large. Internal validation means that only the data of the original 966 
sample are used, i.e. validation is based on the same participant data. If there is optimism then an 967 
important further step is to adjust or shrink the model predictive performance estimates (such as c-968 
index) as well as the predictor effects in the final model. Unfortunately, this is rarely done. The use of 969 
regression coefficients which have not been shrunk or adjusted for optimism will lead to 970 
biased (commonly too extreme) predictions when the unshrunk model is used in other individuals. For 971 
example, a uniform (linear) shrinkage factor, as can be obtained from a bootstrap procedure, might be 972 
applied to all estimated predictor effects. Penalised regression approaches are also becoming popular, 973 
such as ridge regression and Lasso regression, which allow each predictor effect to be shrunk 974 
differently and even allow exclusion of some predictors entirely.(199) Some authors suggest there is 975 
not much difference across different shrinkage methods,(200, 201) but others argue in favour of 976 
penalised approaches.(49, 199) 977 
When developing a prediction model, the need to adjust for model overfitting and optimism is thus 978 
greater for studies with a small sample size, low EPV and studies using stepwise predictor selection 979 
strategies. When internal validation and shrinkage techniques have been used, this signalling question 980 
should be classed as Y. Appropriate adjustments for overfitting alleviate the risk of bias concerns due 981 
to the issues of low EPV (signalling question 4.1), dichotomisation of continuous predictors (signalling 982 
question 4.2), and predictor selection procedures (signalling question 4.5). Studies that develop a 983 
prediction model but do not examine or ignore misfitted models should be rated N for this signalling 984 
question, certainly in presence of small samples, low EPV, categorisation of continuous predictors and 985 
when predictor selection strategies have been used. An exception would be extremely large 986 
development studies with high EPV where overfitting is of limited concern. 987 
Some studies may examine or adjust for optimism but use an inappropriate method. Researchers often 988 
randomly split a dataset at the participant level in two (one for model development and one for 989 
internal validation) which has been shown to be an inadequate way to measure optimism.(154, 202) 990 
Secondly, researchers often apply bootstrapping and cross-validation techniques to examine optimism 991 
but fail to replicate the exact same model development procedure (e.g. predictor selection procedures, 992 
both in univariable analysis and multivariable analysis) and thus may underestimate the actual 993 
optimism for their model.(203, 204) Such inappropriate methods would lead to an N for this signalling 994 
question. 995 
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Example: 
Perel et al. examine the impact of overfitting in their model development by using bootstrapping.(89) The 
authors state: “We drew 200 samples with replacement from the original data, with the same size as the 
original derivation data. In each bootstrap sample, we repeated the entire modelling process, including 
variable selection. We averaged the c-statistics of those 200 models in the bootstrap samples. We then 
estimated the average c-statistic when each of the 200 models was applied in the original sample. The 
difference between the two average c-statistics indicated the “optimism” of the c statistic in our prognostic 
model.” However, although the optimism in the c-statistic was examined, there was no consideration of the 
optimism in absolute risk predictions, and thus no shrinkage factor was applied to the predictor coefficients. 
Nevertheless, the reported optimism in the c-statistic was very small (0.001), i.e. the signalling question should 
be answered as PY or Y. 
In contrast, Rietveld et al. should be answered as PN or N as statistical methods to address overfitting were 
not used.(90) The authors used a predictor selection procedure based first on univariable p-values and then 
on multivariable p-values, and additionally considered interactions between included predictors; thus, there 
is large potential for overfitting. However, no examination of overfitting was made, and no attempt to shrink 
due to optimism was reported. The authors do report using bootstrapping. However, this appears to be used 
as a check on the impact of outliers and estimating confidence intervals, rather than to examine overfitting 
and optimism in discrimination and calibration performance. 
4.9 Do predictors and their assigned weights in the final model correspond to the results from the 996 
reported multivariable analysis? (Model development studies only) 997 
Predictors and coefficients of the final developed model, including intercept or baseline components, 998 
should be fully reported to allow others to correctly apply it to other individuals. A mismatch between 999 
the presented final model and the reported results from the multivariable analysis (e.g. the intercept 1000 
and predictor coefficients) is frequent. A review of prediction models in cancer in 2010 identified only 1001 
13 out of 38 (34%) of final prediction model equations used the same predictors and coefficients of 1002 
the final presented multivariable analyses, 8 used the same predictors but different coefficients, 11 1003 
used neither the same coefficients nor predictors, and in 6 the method to derive the final prediction 1004 
model from the presented results of the multivariable analysis was unclear.(122) 1005 
Bias can arise when there is a mismatch between the presented final model and the results reported 1006 
from the multivariable analysis. One way in which this can occur is the problem of dropping non-1007 
significant predictors from a larger model to arrive at a final presented model but using the predictor 1008 
coefficients from the larger model which are no longer correct. When dropping predictors from a larger 1009 
model it is important to re-estimate all predictor coefficients of the smaller model as this has become 1010 
the final model. These newly estimated predictor coefficients are likely different even if non-significant 1011 
or non-relevant predictors from the larger model are dropped.  1012 
When the study reports the final model where both the predictors and the regression coefficients 1013 
correspond to the reported results of the multivariable regression analysis or model, then this should 1014 
be answered as Y. If the final model presented is only based on a selection of predictors from the 1015 
reported multivariable regression analysis without refitting the smaller model, then this should be 1016 
answered as N or PN. When there is no information on the multivariable modelling where the 1017 
predictors and regression coefficients are derived from, then this should be answered as NI. 1018 
This signalling question is not about detecting improper methods of selecting predictors for the final 1019 
model; methods of selecting predictors is addressed in signalling question 4.5. 1020 
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Example: 
Perel et al. report the final model with odds ratios for each predictor and interaction term, and the model 
formula with predictor coefficients. The full model would be rated as PY or Y as all predictors from the final 
multivariable analysis are included with coefficients derived from the multivariable analysis. Perel et al. also 
include a simplified model that was separately developed and validated, with the coefficient terms refitted in 
the simplified model. If instead the simplified model had not been refitted to correct coefficients for this 
simplified model with fewer predictors, the paper would have been answered as N for this signalling question. 
In Rietveld et al., all predictors in the final model were included in the simplified clinical score but this 
simplified clinical score used whole number scores, presumably to facilitate its usability. However, these 
rounded number scores no longer weighted the predictors based on the final model, as seen for the predictor 
“two glued eyes” where the coefficient of 2.707 was rounded to 5 (multiplied by 1.84), whereas -0.61 was 
rounded to -1 (multiplied by 1.64). The signalling question would be answered N as the assigned weights of 
the predictors do not correspond to the results in the final multivariable analysis. 
Rating the risk of bias for domain 4 1021 
Table 10 shows how the signalling questions should be answered and an overall judgement for 1022 
domain 4 should be reached. 1023 
Tailoring PROBAST with additional signalling questions 1024 
We encourage researchers to also use PROBAST to appraise prediction model studies in which other 1025 
outcome types than binary or time-to-event outcomes (e.g. for ordinal, nominal or continuous 1026 
outcomes) were considered, and for studies using alternative analysis methods to regression-based 1027 
techniques (e.g. tree based, machine or artificial learning techniques). Reviewers may tailor PROBAST 1028 
by adding additional signalling questions to address bias related to these other types of outcomes or 1029 
modelling techniques. For example, when addressing models for prediction of continuous outcomes, 1030 
the signalling question that addresses the number of events per studied predictor (Domain 4) may be 1031 
tailored to address the total number of study participants per studied predictor.(49) When studies 1032 
based on machine or artificial learning techniques are used, most if not all of the signalling questions 1033 
will still apply. Additional questions may need to be added, as these techniques use different predictor 1034 
selection strategies, predictor-outcome estimations and methods to adjust for overfitting. 1035 
Also, when investigating studies on the added predictive value of a specific predictor to an existing 1036 
model, a signalling question can be added that focuses on the methods used for quantifying added 1037 
value, for example net reclassification index (NRI) or decision curve analysis.(85, 205) Similarly, when 1038 
investigating studies that focus on recalibration or updating an existing model to another setting, a 1039 
question on the method of recalibration or updating could be added, for example recalibrating the 1040 
baseline risk or hazard, updating the original regression coefficients, or refitting the entire model.  1041 
Whenever reviewers decide to tailor or add signalling questions, these need to be phrased such that 1042 
the answer “yes” indicates a low risk of bias, to facilitate coherence with current signalling questions. 1043 
Specific guidance on how to assess each added signalling question specific for a review should also be 1044 
produced.  1045 
We do not recommend removing signalling questions from the tool unless they are clearly not relevant 1046 
to a review question. If all studies would rate “yes” or “no” for a particular question, then it is still 1047 
helpful to leave it in the tool. This shows whether a particular source of bias or concern for applicability 1048 
is a potential problem for that review. 1049 
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Step 4 – Overall judgement 1050 
Table 11 shows an overall judgement on the risk of bias and applicability of a prediction model 1051 
evaluation. If a prediction model evaluation is judged as “low” on all domains relating to bias or 1052 
applicability, then it is appropriate to have an overall judgment of “low risk of bias” or “low concern 1053 
for applicability”. If an evaluation is judged “high” for at least one domain, then it should be judged at 1054 
“high risk of bias” or as having “high concerns for applicability.” If the prediction model evaluation is 1055 
“unclear” in one or more domains and was rated as “low” in the remaining domains, then it may be 1056 
judged at “unclear risk of bias” or as having “unclear concerns for applicability”. 1057 
PROBAST should not be used to generate a summary “quality score” for a study because of the well-1058 
known problems associated with such scores.(206, 207) Rather than striving for a summary score, the 1059 
impact of problems within each domain should be judged and discussed. 1060 
Presentation and use of PROBAST assessment into the review 1061 
Presentation of the risk of bias and applicability assessment is an important aspect of communicating 1062 
the strength of evidence in a review. All reviews should include a narrative summary of risk of bias and 1063 
applicability concerns, linked to how this affects interpretation of findings and strength of inferences. 1064 
In addition, a table showing the results of the assessments of risk of bias and applicability concerns of 1065 
all included assessments should be presented. Table 12 is an example to facilitate identification of key 1066 
issues across all included prediction models and their studies. A quick way to summarise across all 1067 
studies is a graphical summary presenting the percentage of studies rated by level of concern risk of 1068 
bias and applicability for each domain (see Figure 1). This is in line with item 22 of the PRISMA 1069 
statement of how to report systematic reviews and meta-analyses of studies that evaluate health care 1070 
interventions (PRISMA).(39, 40) It should be noted that these summaries are not sufficient on their 1071 
own, i.e. without an accompanying discussion of what any observed patterns mean for the evidence 1072 
base in relation to the review question. 1073 
Further incorporation of risk of bias and concerns for applicability may be specified in the review 1074 
planning stage or in the systematic review protocol. Findings can be included in the analysis by planning 1075 
sensitivity analyses limited to studies with low concerns for risk of bias or applicability either overall or 1076 
for particular domains, or investigation of heterogeneity between studies using subgroups based on 1077 
ratings of concern.(20) 1078 
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Concluding remarks 1079 
(308 words) 1080 
PROBAST is the first rigorously developed tool designed specifically to assess the risk of bias and 1081 
concerns for applicability of primary studies on development, validation or updating (including 1082 
extension) of prediction models to be used for individualised predictions. PROBAST covers both 1083 
diagnostic and prognostic models, regardless of the medical domain, type of outcome, predictors or 1084 
statistical technique used. 1085 
This E&E paper provides explicit guidance on how to use PROBAST (REF M18-1376), including how to 1086 
interpret each signalling question, how to grade the risk of bias per domain and overall, and how to 1087 
present and incorporate PROBAST assessments in a systematic review, all accompanied with generic 1088 
guidance on diagnostic and prognostic prediction model research. This detailed explanation and 1089 
elaboration for PROBAST will enable a focussed and transparent approach to assessing the risk of bias 1090 
and applicability of studies developing, validating or updating of prediction models for individualised 1091 
predictions. Six worked-out examples of PROBAST assessments, covering development studies, 1092 
validation studies, a combination of both and addressing both diagnostic and prognostic models can 1093 
be found at our website www.probast.org. We also encourage and will make available translations of 1094 
PROBAST. 1095 
The use of PROBAST requires expertise and knowledge of prediction model researchers as well as 1096 
clinicians. Guidance on methods for prediction model research is still at an early stage compared to 1097 
guidance on methods and interpretation of randomised intervention studies and diagnostic test 1098 
accuracy studies. We recognise that currently necessary information for assessment of bias and 1099 
applicability is often not reported, and hope that adherence of both journals and authors to the TRIPOD 1100 
reporting guideline (7, 8) will reduce this problem.  1101 
As with other risk of bias and reporting guidelines in medical research, PROBAST and its guidance will 1102 
require updating, as methods for prediction model studies develop. We recommend downloading the 1103 
latest version of PROBAST tool and guidance from the website (www.probast.org).  1104 
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PROBAST: a tool to assess risk of bias and 
applicability of prediction model studies – 
explanation and elaboration 
 
Table 1. Guidance on conducting systematic reviews of prediction model studies 
Task Guidance 
Reporting of primary study Transparent reporting of prediction models for prognosis and 
diagnosis (TRIPOD)(7, 8) 
Defining review question and 
developing criteria for including 
studies*  
Guidance for defining review question and design of the review of 
prognosis studies , see Table 4 (CHARMS)(19) (20) 
Guidance for protocol for diagnostic test accuracy (DTA) reviews(23, 24) 
Searching for studies* Search filters for prediction studies(18) 
https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/filters-
to-identify-studies-about-prognosis 
Search for DTA studies(25) 
Selecting studies and extracting 
data*  
Guidance and checklist for data extraction and critical appraisal of 
prognosis studies (CHARMS)(19). Guidance for DTA studies(24, 26) 
Assessing risk of bias and 
applicability in included studies*  
Prediction model Risk Of Bias Assessment Tool (PROBAST)[REF M18-1376] 
Analysing data and undertaking 
meta-analyses*  
Meta-analysis of prediction models(20, 27-30); Meta-analysis of 
diagnostic test accuracy studies(31-38) 
Interpreting results and 
drawing conclusions* 
PROBAST [REF M18-1376] 
Guidance for interpretation of results(20, 27-29) 
Guidance for interpretation of diagnostic test accuracy studies(24) 
Reporting of systematic reviews Transparent reporting of systematic reviews and meta-
analysis (PRISMA)(39-41) 
Assessing risk of bias of 
systematic reviews 
Risk of bias in systematic reviews (ROBIS)(42) 
* Step in line with the general methods for Cochrane Reviews(43) 
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Table 2. PICOTS 
Six key items (the so-called PICOTS) to guide the framing of the review aim. PICOTS is a modification of the traditional PICO system used in systematic reviews of 
therapeutic intervention studies, by adding Timing (the time point of using the prediction model and the time period of the prediction) and clinical Setting(19, 
20) 
Item Comments  
1. Population Define the target population in which the prediction model(s) under review will be used. 
2. Index  Define the prediction model(s) under review.  
3. Comparator If applicable, define whether other prediction models are reviewed and compared to the index model 
4. Outcome(s) Define the outcome(s) of interest for the model(s) under review. 
5. Timing Define at what moment or time-point (e.g. in the patient work-up) the prediction model(s) under review are to be used in the 
targeted population, and over what time period the outcome(s) are predicted (the latter in case of prognostic models).  
6. Setting  Define the intended clinical setting of the prediction model(s) under review. 
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Table 3. Four steps in PROBAST 
Step Task When to complete 
1 Specify your systematic review 
question(s) 
Once per systematic review 
2 Classify the type of prediction model 
evaluation 
Once for each model of interest in each 
publication being assessed, for each relevant 
outcome 
3 Assess risk of bias and applicability (per 
domain) 
Once for each development and validation of 
each distinct prediction model in a publication 
4 Overall judgment of risk of bias and 
applicability 
Once for each development and validation of 
each distinct prediction model in a publication 
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Table 4. Example papers 
Author 
(Year) 
Topic area Type of prediction 
model 









Dev+Val Prog Non-nested case-control 
study, population of 

























Mortality (14 day, 
6 months), 
unfavourable 








Val Diag Prospective cross-
sectional study, 
110 primary care practices 
in the Netherlands (Val: 
01/2002 – 03/2003)  
Symptomatic DVT History taking, 
physical 
examination 







Dev+Val Prog Dev: Randomised 
controlled trial, 
274 hospitals in 
40 countries (no dates 
reported) 
Trauma or risk of 
significant 
bleeding 




Mortality Dev: 20127 Yes Yes 
Val: Registry, 60% of 
trauma hospitals in 
England and Wales (2000-
2008) 





Dev Diag Cohort study, 25 care 
centres in NL (09/1999-
12/2002) 
Red eye + (muco-) 
purulent discharge 






184 (57) Yes Yes 
Cal = Calibration; Dev = Development; Diag = Diagnostic; Discr. = Discrimination; DVT = deep vein thrombosis; GCS = Glasgow Coma Scale; MI = Myocardial infarction; NL = The Netherlands; Prog = Prognostic; Ref = 
Refinement; TBI = Traumatic brain injury; Val = Validation 
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Table 5. Example Step 1 applied to the Perel example study(89) 
Criteria Specify your systematic review question:  
Intended use of model:  Prognosis; At presentation at hospital accident and 
emergency 
Participants including selection criteria 
and setting: 
Trauma patients presenting at accident and emergency. 
Predictors (used in modelling) 
including (1) types of predictors (e.g. 
history, clinical examination, 
biochemical markers, imaging tests), 
(2) time of measurement, (3) specific 
measurement issues (e.g. any 
requirements/ prohibitions for 
specialised equipment): 
Patients’ demographics; Physiological variables; Injury 
characteristics; Time from injury -- all measured at 
presentation to A&E.  
Imaging with results available within 4 hours of 
admission 
Key predictors to include: type of injury 
Outcome to be predicted:  Death within 4 weeks of injury 
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Definitions for type of prediction model study 
Development 
only 
Dev  Prediction model development without external 
validation. These studies may include internal 




Dev and Val  Prediction model development combined with 




Val  External validation of existing (previously 
developed) model in other participants  
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Table 7. Participants domain: guidance notes for rating risk of bias and applicability 
Domain 1: Participants 
Risk of bias assessment 
Background:  
The overall aim for prediction models is to generate absolute risk predictions that are correct in new 
individuals. Certain data sources or designs are not suited to generate absolute probabilities. Problems 
may also arise if a study inappropriately includes or excludes participant groups from entering the 
study. 
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control study data? 
Yes/ Probably yes If a cohort design (including RCT or proper registry data) or a nested case-control 
or  case-cohort design (with proper adjustment of the baseline risk/hazard in the 
 analysis) has been used. 
No/ Probably no If a non-nested case-control design has been used. 
No information If the method of participant sampling is unclear. 
1.2 Were all inclusions and exclusions of participants appropriate? 
Yes/ Probably yes If inclusion and exclusion of participants was appropriate, so participants 
 correspond to unselected participants of interest. 
No/ Probably no If participants are included who would already have been identified as having the 
 outcome by prior tests and so are no longer participants at suspicion of disease 
 (diagnostic studies) or at risk of developing outcome (prognostic studies) 
 or if specific subgroups are excluded that may have altered the performance of 
the  model for the intended target population. 
No information When there is no information on whether inappropriate in- or exclusions took 
place.  
Risk of bias introduced by participants or data sources: 
Low risk of bias If the answer to all signalling questions is “Yes” or “Probably Yes” then risk of bias 
 can be considered low. 
 If one or more of the answers is “No” or “Probably no”, the judgement could still 
 be  “Low risk of bias” but specific reasons should be provided why the risk of bias 
 can be considered low. 
High risk of bias If the answer to any of the signalling questions is “No” or “Probably no” there is a 
 potential for bias, except if defined at low risk of bias above. 
Unclear risk of bias If relevant information is missing for some of the signalling questions and none of 
 the signalling questions is judged to put this domain at high risk of bias. 
Concerns for applicability 
Background:  
Included participants, the selection criteria used as well as the setting used in the primary study should 
be relevant to the review question. 
Concern that included participants or the setting do not match the review question: 
Low concern  Included participants and clinical setting match the review question. 
for applicability 
High concern Included participants and clinical setting were different from the review question. 
for applicability  
Unclear concern If relevant information about the participants is not reported. 
for applicability 
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Table 8. Predictors domain: guidance notes for rating risk of bias and applicability 
Domain 2: Predictors 
Risk of bias assessment 
Background:  
Bias in model performance can occur when the definition and measurement of predictors is flawed. 
Predictors are the variables evaluated for their association with the outcome of interest. Bias can occur, 
for example when predictors are not defined in a similar way for all participants or knowledge of the 
outcome influences predictor assessments. 
2.1 Were predictors defined and assessed in a similar way for all participants? 
Yes/ Probably yes If definitions of predictors and their assessment were similar for all participants. 
No/ Probably no If different definitions were used for the same predictor or if predictors requiring 
 subjective interpretation were assessed by differently experienced assessors. 
No information If there is no information on how predictors were defined or assessed. 
2.2 Were predictor assessments made without knowledge of outcome data? 
Yes/ Probably yes If outcome information was stated as not used during predictor assessment or 
was  clearly not available to those assessing predictors. 
No/ Probably no If it is clear that outcome information was used when assessing predictors. 
No information No information on whether predictors were assessed without knowledge of 
 outcome information. 
2.3 Are all predictors available at the time the model is intended to be used? 
Yes/ Probably yes All included predictors would be available at the time the model would be used 
for  prediction. 
No/ Probably no Predictors would not be available at the time the model would be used for 
 prediction. 
No information No information on whether predictors would be available at the time the model is 
 intended to be used. 
Risk of bias introduced by predictors or their assessment: 
Low risk of bias If the answer to all signalling questions is “Yes” or “Probably Yes” then risk of bias 
 can be considered low. 
 If one or more of the answers is “No” or “Probably no”, the judgement could still 
 be  “Low risk of bias” but specific reasons should be provided why the risk of bias 
 can be considered low, e.g. use of objective predictors not requiring subjective 
 interpretation. 
High risk of bias If the answer to any of the signalling questions is “No” or “Probably no” there is a 
 potential for bias. 
Unclear risk of bias If relevant information is missing for some of the signalling questions and none of 
 the signalling questions is judged to put the domain at high risk of bias. 
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Domain 2: Predictors 
Concerns for applicability 
Background:  
The definition, assessment and timing of predictors in the primary study should be relevant to the 
review question, for example predictors should be measured using methods potentially applicable to 
the daily practice that is addressed by the review. 
Concern that the definition, assessment or timing of predictors in the model do not match the review 
question: 
Low concern  Definition, assessment and timing of predictors match the review question. 
for applicability 
High concern Definition, assessment or timing of predictors was different from the review 
for applicability question. 
Unclear concern If relevant information about the predictors is not reported. 
for applicability 
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Table 9. Outcome domain: guidance notes for rating risk of bias and applicability 
Domain 3: Outcome 
Risk of bias assessment 
Background:  
Bias in model performance can occur when methods used to determine outcomes incorrectly classify 
participants with or without the outcome. Bias in methods of outcome determination can result from 
use of suboptimal methods, tests or criteria that lead to unacceptably high levels of errors in outcome 
determination, when methods are inconsistently applied across participants, and when knowledge of 
predictors influence outcome determination. Incorrect timing of outcome determination can also result 
in bias.  
3.1 Was the outcome determined appropriately? 
Yes/ Probably yes If a method of outcome determination has been used which is considered 
 optimal or acceptable by guidelines or previous publications on the topic.  
 Note: This is about level of measurement error within the method of determining 
 outcome (see concerns for applicability about whether the definition of the 
 outcome method is appropriate). 
No/ Probably no If a clearly suboptimal method has been used that causes unacceptable error in 
determining outcome status in participants. 
No information No information on how outcome was determined. 
3.2 Was a pre-specified or standard outcome definition used? 
Yes/ Probably yes If the method of outcome determination is objective  or if a standard outcome 
definition is used or if pre-specified categories are used to group outcomes. 
No/ Probably no If the outcome definition was not standard and not pre-specified. 
No information No information on whether the outcome definition was pre-specified or standard. 
3.3 Were predictors excluded from the outcome definition? 
Yes/ Probably yes If none of the predictors are included in the outcome definition. 
No/ Probably no If one or more of the predictors forms part of the outcome definition. 
No information No information on whether predictors are excluded from the outcome definition. 
3.4 Was the outcome defined and determined in a similar way for all participants? 
Yes/ Probably yes If outcomes were defined and determined in a similar way for all participants. 
No/ Probably no If outcomes were clearly defined and determined in a different way for some 
participants. 
No information No information on whether outcomes were defined or determined in a similar 
way.  for all participants. 
3.5 Was the outcome determined without knowledge of predictor information? 
Yes/ Probably yes If predictor information was not known when determining the outcome status, 
 or outcome status determination is clearly reported as determined without 
knowledge of  predictor information. 
No/ Probably no If it is clear that predictor information was used when determining the 
 outcome status. 
No information No information on whether outcome was determined without knowledge of 
 predictor information. 
3.6 Was the time interval between predictor assessment and outcome determination appropriate? 
Yes/ Probably yes If the time interval between predictor assessment and outcome determination 
 was appropriate to enable the correct type and representative number of 
relevant  outcomes to be recorded, or if no information on the time interval is required to 
 allow a representative number of the relevant outcome occur or if predictor 
 assessment and outcome determination were from samples or information taken 
 within an appropriate time interval. 
Page 11 of 20 
Domain 3: Outcome 
No/ Probably no If the time interval between predictor assessment and outcome determination is 
 too short or too long to enable the correct type and representative number of 
relevant  outcomes to be recorded. 
No information If no information was provided on the time interval between predictor 
 assessment and outcome determination. 
Risk of bias introduced by predictors or their assessment: 
Low risk of bias If the answer to all signalling questions is “Yes” or “Probably yes” then risk of bias 
 can be considered low. 
 If one or more of the answers is “No” or “Probably no”, the judgement could still 
 be  low risk of bias, but specific reasons should be provided why the risk of bias 
 can be considered low, e.g. when the outcome was determined with knowledge 
 of predictor information but the outcome assessment did not require much 
 interpretation by the assessor (e.g. death regardless of cause). 
High risk of bias If the answer to any of the signalling questions is “No” or “Probably no” there is a 
 potential for bias. 
Unclear risk of bias If relevant information about the outcome is missing for some of the signalling 
 questions and none of the signalling questions is judged to put this domain at 
 high risk of bias. 
Concerns for applicability 
Background: 
The definition of outcome in the primary study should be relevant for the outcome definition in the 
review question.  
Concern that the outcome definition, timing or determination do not match the review question: 
Low concern  Outcome definition, timing and method of determination defines the outcome 
for applicability as intended by the review question. 
High concern Choice of outcome definition, timing and method or determination defines 
another for applicability outcome as intended by the review question. 
Unclear concern If relevant information about the outcome, timing and method of determination 
for applicability is not reported. 
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Table 10. Analysis domain: guidance notes for rating risk of bias 
Domain 4: Analysis 
Risk of bias assessment 
Background:  
Statistical analysis is a critical part of prediction model development and validation. The use of 
inappropriate statistical analysis methods increases the potential for bias in reported model performance 
measures. Model development studies include many steps where flawed methods can distort results. 
We recommend reviewers seek statistical advice when completing assessments of the analysis domain. 
4.1 Were there a reasonable number of participants with the outcome? 
Yes/ Probably yes For model development studies, if the number of participants with the outcome 
 relative to the number of candidate predictor parameters is 20 or more (EPV ≥ 
20).* 
 For model validation studies, if the number of participants with the outcome is 
 100 or more. 
No/ Probably no For model development studies, the number of participants with the outcome 
 relative to the number of candidate predictor parameters is less than 10 (EPV< 
10).* 
 For model validation studies, if the number of participants with the outcome is 
 less than 100. 
No information For model development studies, no information on the number of candidate 
 predictor parameters or number of participants with the outcome, such that the 
EPV  cannot be calculated. 
 For model validation studies, no information on the number of participants with 
 the outcome. 
* For EPVs between 10 and 20 the item should be rated as either probably yes or probably no, 
depending on the outcome frequency, overall model performance, and distribution of the predictors in 
the model. For more guidance see these references: (144-146)  
4.2 Were continuous and categorical predictors handled appropriately?  
Yes/ Probably yes If continuous predictors are not converted into two or more categories when  
 included in the model (i.e. dichotomised or categorised),  
 or if continuous predictors are examined for nonlinearity using, for example, 
 fractional polynomials or restricted cubic splines  
 or if categorical predictor groups are defined using a pre-specified method. 
No/ Probably no If categorical predictor groups definitions do not use a pre-specified method. 
 For model development studies, if continuous predictors are converted into two 
 or more categories when included in the model. 
 For model validation studies, if continuous predictors or categorical variables are 
 categorised using different cut-points compared to the development study. 
No information No information on whether continuous predictors are examined for non-linearity. 
 No information on how categorical predictor groups are defined,  
 or no information on whether the same cut-points are used in the validation as 
 compared to the development study. 
4.3 Were all enrolled participants included in the analysis?  
Yes/ Probably yes If all participants enrolled in the study are included in the data analysis. 
No/ Probably no If some or a subgroup of participants are inappropriately excluded from the 
 analysis 
No information No information on whether all enrolled participants are included in the analysis. 
4.4 Were participants with missing data handled appropriately?  
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Yes/ Probably yes If there are no missing values of predictors or outcomes and the study explicitly 
 reports that participants are not excluded on the basis of missing data, 
 or if missing values are handled using multiple imputation. 
No/ Probably no If participants with missing data are omitted from the analysis, 
 or if the method of handling missing data is clearly flawed e.g. missing indicator 
method or inappropriate use of last value carried forward, 
 or if the study had no explicit mention of methods to handle missing data. 
No information If there is insufficient information to determine if the method of handling missing 
 data is appropriate. 
4.5 Was selection of predictors based on univariable analysis avoided? [Development only] 
Yes/ Probably yes If the predictors are not selected based on univariable analysis prior to 
multivariable modelling.  
No/ Probably no If the predictors are selected based on univariable analysis prior to multivariable 
modelling.  
No information If there is insufficient information to indicate that univariable selection is avoided. 
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of controls) accounted 
for appropriately? 
Yes/ Probably yes If any complexities in the data are accounted for appropriately, 
 or if it is clear that any potential data complexities have been identified 
 appropriately as unimportant. 
No/ Probably no If complexities in the data that could affect model performance are ignored. 
No information No information is provided on whether complexities in the data are present or 
 accounted for appropriately if present. 
4.7 Were relevant model performance measures evaluated appropriately? 
Yes/ Probably yes If both calibration and discrimination are evaluated appropriately (including 
 relevant measures tailored for models predicting survival outcomes) 
No/ Probably no If both calibration and discrimination are not evaluated, 
 or if only goodness-of-fit tests, such as the Hosmer-Lemeshow test are used to 
 evaluate calibration, 
 or if for models predicting survival outcomes performance measures accounting 
 for censoring are not used, 
 or if classification measures (like sensitivity, specificity or predictive values) were 
 presented using predicted probability thresholds derived from the dataset at 
hand. 
No information Either calibration or discrimination are not reported, 
 or no information is provided as to whether appropriate performance measures 
 for survival outcomes are used (e.g. references to relevant literature or specific 
 mention of methods such as using Kaplan-Meier estimates)  
 or no information on thresholds for estimating classification measures is given. 
4.8 Was model overfitting and optimism in model performance accounted for? [Development only] 
Yes/ Probably yes If internal validation techniques, such as bootstrapping and cross-validation have 
 been used to account for any optimism in model fitting, and subsequent 
adjustment  of the prediction model performance and presented model parameters have 
been  applied. 
No/ Probably no If no internal validation has been performed, 
 or if internal validation consists only of a single random split-sample of participant 
 data,  
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 or if the bootstrapping or cross-validation did not include all model development 
 procedures including any variable selection  
No information No information is provided on whether all model development procedures are 
 included in the internal validation techniques. 
4.9 Do predictors and their assigned weights in the final model correspond to the results from the 
reported multivariable analysis? [Development only] 
Yes/ Probably yes If the predictors and regression coefficients in the final model correspond to 
 reported results from multivariable analysis. 
No/ Probably no If the predictors and regression coefficients in the final model do not correspond 
 to reported results from multivariable analysis. 
No information If it is unclear whether the regression coefficients in the final model correspond to 
 reported results from multivariable analysis. 
Risk of bias introduced by the analysis: 
Low risk of bias If the answer to all signalling questions is “Yes” or “Probably yes” then risk of bias 
 can be considered low. 
 If one or more of the answers is “No” or “Probably no”, the judgement could still 
 be low risk of bias, but specific reasons should be provided why the risk of bias 
 can be considered low.  
High risk of bias If the answer to any of the signalling questions is “No” or “Probably no” there is a 
 potential for bias. 
Unclear risk of bias If relevant information about the analysis is missing for some of the signalling 
 questions but none of the signalling question answers is judged to put the 
 analysis at high risk of bias. 
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Table 11. Overall assessment of risk of bias and concerns for applicability 
Reaching an overall judgement of risk of bias of the prediction model evaluation 
Low risk of bias  If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was 
rated as low risk of bias for all domains, consider downgrading to high risk of 
bias. Such a model evaluation can only be considered as low risk of bias, if the 
development was based on a very large data set and included some form of 
internal validation. 
High risk of bias  If at least one domain is judged to be at high risk of bias.  
Unclear risk of bias If an unclear risk of bias was noted in at least one domain and it was low risk for 
all other domains.  
 
Reaching an overall judgement of concerns for applicability of the prediction model evaluation 
Low concerns for 
applicability  
If low concerns for applicability for all domains, the prediction model evaluation 
is judged to have low concerns for applicability. 
High concerns for 
applicability  
If high concerns for applicability for at least one domain, the prediction model 
evaluation is judged to have high concerns for applicability. 
Unclear concerns for 
applicability  
If unclear concerns (but no “high concern”) for applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns for 
applicability overall. 
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Table 12. Suggested Tabular Presentation for PROBAST Results 
Study Risk of bias Applicability Overall 
Participants Predictors Outcome Analysis Participants Predictors Outcome Risk of 
bias 
Applicability 
Study 1 + - ? + + + + - + 
Study 2 + + + + + + + + + 
Study 3 + + + ? - + + ? - 
Study 4 - ? ? - + + - - - 
Study 5 + + + + + ? + + ? 
Study 6 + + + + ? + ? + ? 
Study 7 ? ? + ? + + + ? + 
Study 8 + + + + + + + + + 
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Box 1. Types of diagnostic and prognostic modelling studies or reports addressed by PROBAST 
(adopted from the TRIPOD and CHARMS guidance(8, 19)) 
Prediction model development without external validation 
These studies aim to develop one or more prognostic or diagnostic prediction models from a specific 
development data set. They aim to identify the important predictors of the outcome under study, assign 
weights (e.g. regression coefficients) to each predictor using some form of multivariable analysis, develop a 
prediction model to be used for individualised predictions, and quantify the predictive performance of that 
model in the development set. Sometimes, model development studies may also focus on adding one or more 
new predictors to established predictors. In any prediction model study, overfitting may occur, particularly in 
small data sets. Hence, development studies should include some form of resampling or "internal 
validation” (internal because the same data are used for both development and internal validation), such as 
bootstrapping or cross-validation. These methods quantify any optimism (bias) in the predictive performance 
of the developed model. 
 
Prediction model development with external validation 
Studies that have the same aim as the previous type, but the development of the model is followed by 
quantifying the model predictive performance in data external to the development sample i.e. from different 
participants. This may be data collected by the same investigators, commonly using the same predictor and 
outcome definitions and measurements, but sampled from a later time period (temporal validation); by other 
investigators in another hospital or country, sometimes using different definitions and measurements 
(geographic validation); in similar participants, but from an intentionally chosen different setting (e.g. model 
developed in secondary care and tested in similar participants from primary care); or even in other types of 
participants (e.g. model developed in adults and tested in children). Randomly splitting a single data set into 
a development and a validation data set is often erroneously referred to as a form of external validation, but 
actually is an inefficient form of "internal" validation, because the two so created data sets only differ by 
chance and sample size of model development is reduced. 
When a model predicts poorly when validated in other data, a model validation can be followed by 
adjusting (or updating the existing model (e.g. by recalibration of the baseline risk or hazard or adjusting the 
weights of the predictors in the model) to the validation data set at hand, and even by extending the model 
by adding new predictors to the existing model. In both situations in fact a new model is being developed after 
the external validation of the existing model. 
 
Prediction model external validation 
These studies aim to assess the predictive performance of one or more existing prediction models by using in 
data external to the development sample i.e. from different participants.  
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Box 2. Differences between diagnostic and prognostic prediction model studies 
Diagnostic prediction models aim to estimate the probability that a target condition measured using a 
reference standard (referred to as outcome in PROBAST) is currently present or absent within an individual. 
In diagnostic prediction model studies, the prediction is for an outcome already present so the preferred 
design is a cross-sectional study although sometimes follow-up is used as part of the reference test to 
determine the target condition presence at the moment of prediction. 
 
Prognostic prediction models estimate whether an individual will experience a specific event or outcome in 
the future within a certain time period, ranging from minutes to hours, days, weeks, months or years: always 
a longitudinal relationship. 
 
Despite the different timing of the predicted outcome, there are many similarities between diagnostic and 
prognostic prediction models, including the:  
 Type of outcome is often binary (target condition or disease presence (yes/no) or future occurrence 
of an outcome event (yes/no).  
 Key interest is to estimate the probability of an outcome being present or occurring in the future 
based on multiple predictors with the purpose of informing individuals and guiding decision-
making. 
 Same challenges occur when developing or validating multivariable prediction models. The same 
measures for assessing predictive performance of the model can be used, although diagnostic 
models more frequently extend assessment of predictive performance to focus on thresholds of 
clinical relevance. 
 
There are also various differences in terminology between diagnostic and prognostic model studies: 
 
Diagnostic prediction model study Prognostic prediction model study 
Predictors 
Diagnostic tests or index tests Prognostic factors or prognostic indicators 
Outcome 
Reference standard used to assess or verify 
presence/absence of target condition 
Event (future occurrence yes or no) 
Event measurement 
Missing outcome assessment 
Partial verification, lost to follow-up Lost to follow-up and censoring 
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Box 3. Examples of systematic review questions for which PROBAST is suitable 
There are various different questions that systematic reviews of prediction models may address. The following 
are examples of different types of review in which PROBAST can be applied. 
 
A specific target population  
 Review of all models developed or validated for predicting the risk of incident type 2 diabetes in the 
general population.(58) 
 Review of all prognostic models developed or validated for use in patients diagnosed with acute 
stroke.(59) 
 
A specific outcome 
 Review of all diagnostic models developed or validated for detecting venous thromboembolism 
regardless the type of patients.(60) 
 Review of all prognostic models developed or validated for predicting loss of daily activity, regardless 
the type of patients.(61) 
  
A particular clinical field: 
 Review of all prognostic models developed or validated in reproductive medicine.(62) 
 Review of all prognostic models developed or validated in acute care of traumatic brain injury.(63) 
 
A specific prediction model:  
 Review of the predictive performance of the EuroSCORE (a model to predict operative mortality 
following cardiac surgery) as found across all external validation studies of the EuroSCORE model.(64) 
 Review to compare the predictive performance of various prognostic models for developing 
cardiovascular disease in middle aged individuals in the general populations, across all validation 
studies of these models.(65) 
 
A specific predictor:  
 Meta-analysis of the added predictive value of C-reactive protein when added to the Framingham 
risk model.(66) 
 Meta-analysis of the added predictive value of carotid artery imaging to an existing cardiovascular 
risk prediction model.(67) 
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Box 4. Prediction model performance measures 
Calibration reflects the agreement between predictions from the model and observed outcomes. Calibration 
is preferably reported graphically, with observed risks plotted on the y-axis against predicted risks on the x-
axis. This plot is commonly done by tenths of the predicted risk and is preferably augmented by a 
smoothed (lowess) line over the entire predicted probability range. This is possible both for prediction models 
developed by logistic regression(49, 76, 77) and by survival modelling(78, 79). The calibration plot displays the 
direction and magnitude of any model miscalibration across the entire predicted probability range, which can 
be combined with estimates of the calibration slope and intercept.(79, 80) Calibration is frequently assessed 
by calculating the Hosmer-Lemeshow goodness-of-fit test, however, this test has limited suitability to evaluate 
poor calibration and is sensitive to the numbers of groups and sample size: the test is often non-significant for 
small datasets and nearly always significant for large datasets. Studies reporting only the Hosmer-Lemeshow 
test with no calibration plot or a table comparing the predicted versus observed outcome frequencies provide 
no useful information on the accuracy of the predicted risks (see signalling question 4.7). 
Discrimination refers to the ability of a prediction model to distinguish between individuals who do or do not 
experience the outcome event. The most general and widely reported measure of discrimination, for both 
logistic and survival models, is the concordance index (c-index), which is equivalent to the area under the 
receiver operating characteristic curve for logistic regression models.  
Calibration and discrimination measures should take into account the type of outcome being predicted. For 
survival models, researchers should appropriately account for time-to-event and censoring, e.g. Harrell’s c-
index, D statistic.(81-83)  
 
Many other model predictive performance measures are available including measures to express model 
classification abilities such as sensitivity, specificity and reclassification (e.g. the Net Reclassification Index) 
parameters.(80) These measures can be estimated after introducing one (or more) thresholds in the range of 
the model estimated probabilities. Classification measures are frequently used in diagnostic test accuracy 
studies but less in prediction model studies. Categorization of the predicted probabilities in two or more 
probability categories for estimation of classification measures can lead to loss of information, since the entire 
range of predicted probabilities of the model is not fully utilised. Using thresholds can allow discrimination to 
be reported at potentially clinically relevant thresholds as opposed to across all potential thresholds which 
may not be clinically important. However, introducing probability thresholds implies that the chosen threshold 
is relevant to clinical practice which often is not the case since these thresholds are often data driven yielding 
biased classification parameters.(84) Authors should rather assess these measures based on the general 
principles of pre-specifying (probability) thresholds (see also signalling question 4.2) to avoid multiple testing 
of thresholds and potential selective reporting of thresholds based on the data itself.  
 
There are many other measures of performance measure including net benefit measures and decision curve 
analysis.(85) Many of these measures provide a link between probability thresholds and false-positive and 
false-negative results to obtain the model net benefit at a particular threshold. Net benefit measures are not 
commonly reported for prediction modelling studies. 
 
All the above model performance measures, when estimated on the development data, are often optimistic 
due to overfitting or choosing optimal thresholds, and should therefore be estimated using bootstrapping or 
cross-validation methods (see signalling question 4.8). 
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